var title_f11_49_12048="Herpes zoster rash A";
var content_f11_49_12048=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Herpes zoster",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vaibhav Parekh, MD, MBA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_49_12048=[""].join("\n");
var outline_f11_49_12048=null;
var title_f11_49_12049="Idiopathic chondrolysis of the hip";
var content_f11_49_12049=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    Plain radiographs: Idiopathic chondrolysis of the hip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The hallmark of idiopathic chondrolysis of the hip is narrowing of the hip joint space without frank osteophyte formation in conjunction with periarticular osteopenia in a young female. The plain radiographs A and B above depict bilateral idiopathic chondrolysis of the hip. Note the concentric and uniform narrowing of the joint space bilaterally. Also observe the bilateral protrusio acetabuli (arrows) and periarticular osteopenia. Both of these hips were active on nuclear bone scan.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_49_12049=[""].join("\n");
var outline_f11_49_12049=null;
var title_f11_49_12050="Urine output in urinary tract obstruction and postobstructive diuresis";
var content_f11_49_12050=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Urine output in urinary tract obstruction and postobstructive diuresis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/49/12050/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/49/12050/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/49/12050/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/49/12050/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/49/12050/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/49/12050/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/49/12050/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two commonly held misconceptions concerning the urine output in bilateral urinary tract obstruction (UTO). The first is related to the urine output during the period of obstruction. It is often assumed that the patient should be oliguric or even anuric in this setting. The second misconception is that fluid that is lost due to a postobstructive diuresis should be completely replaced.",
"   </p>",
"   <p>",
"    This topic addresses urinary output in partial urinary tract obstruction and postobstructive diuresis. The recovery of renal function following relief of obstruction and the diagnosis of obstruction are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24276?source=see_link\">",
"     \"Recovery of renal function after relief of urinary tract obstruction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5250547\">",
"    <span class=\"h1\">",
"     URINE OUTPUT IN PARTIAL URINARY TRACT OBSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although anuria is present if urinary tract obstruction is complete, patients with partial obstruction may have a urine output that remains within the normal range or may even be increased due to a secondary concentrating defect.",
"   </p>",
"   <p>",
"    The ability to maintain a normal urine output reflects the fact that the latter is determined by the difference between the glomerular filtration rate and tubular reabsorption. Thus, a marked reduction in GFR from the normal of 150 to 180",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    down to 10",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    will be associated with a daily urine output of 2 L if only 8 L is reabsorbed. This may be particularly likely with the tubular damage caused by chronic obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36456?source=see_link\">",
"     \"Urine output and residual renal function in renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In summary, complete obstruction is one of the major causes of anuria; however, a urine output above 1",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    does not exclude obstruction as the cause of renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5250554\">",
"    <span class=\"h1\">",
"     POSTOBSTRUCTIVE DIURESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urine output after the release of bilateral UTO may initially exceed 500 to 1000",
"    <span class=\"nowrap\">",
"     mL/h.",
"    </span>",
"    Most of the polyuria in this setting is",
"    <strong>",
"     appropriate",
"    </strong>",
"    , representing an attempt to excrete the fluid retained during the period of obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12050/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. As a result, replacing each mL of urine output will lead to persistent volume expansion and a diuresis that can be greater than 10",
"    <span class=\"nowrap\">",
"     L/day.",
"    </span>",
"   </p>",
"   <p>",
"    Optimal",
"    therapy consists of the administration of normal replacement fluids, such as 75",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    of one-half isotonic saline. Although the diuresis is largely appropriate, some fluid therapy is required since there is often a mild sodium-wasting tendency, the severity of which is limited by the concurrent reduction in glomerular filtration rate, and a modest concentrating defect due to downregulation of water channels [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12050/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Although the risk of volume depletion is minimal with this regimen, the patient should be monitored for such signs as hypotension, decreased skin turgor, or a rise in the BUN. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24276?source=see_link\">",
"     \"Recovery of renal function after relief of urinary tract obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5250160\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with partial obstruction may have a normal or even increased urine output. (See",
"      <a class=\"local\" href=\"#H5250547\">",
"       'Urine output in partial urinary tract obstruction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The urine output after the release of bilateral urinary tract obstruction may initially exceed 500 to 1000",
"      <span class=\"nowrap\">",
"       mL/h.",
"      </span>",
"      Most of the polyuria in this setting is",
"      <strong>",
"       appropriate",
"      </strong>",
"      and should not be completely replaced. However, some fluid therapy is required since there is often a mild sodium-wasting tendency. Optimal therapy consists of the administration of normal replacement fluids, such as 75",
"      <span class=\"nowrap\">",
"       mL/h",
"      </span>",
"      of one-half isotonic saline. (See",
"      <a class=\"local\" href=\"#H5250554\">",
"       'Postobstructive diuresis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following the release of bilateral urinary tract obstruction, patients should be monitored for signs of volume depletion such as hypotension, decreased skin turgor, or a rise in the BUN. (See",
"      <a class=\"local\" href=\"#H5250554\">",
"       'Postobstructive diuresis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24276?source=see_link\">",
"       \"Recovery of renal function after relief of urinary tract obstruction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12050/abstract/1\">",
"      Howards SS. Post-obstructive diuresis: a misunderstood phenomenon. J Urol 1973; 110:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12050/abstract/2\">",
"      Bishop MC. Diuresis and renal functional recovery in chronic retention. Br J Urol 1985; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12050/abstract/3\">",
"      Klahr S. New insights into the consequences and mechanisms of renal impairment in obstructive nephropathy. Am J Kidney Dis 1991; 18:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12050/abstract/4\">",
"      Gillenwater JY, Westervelt FB Jr, Vaughan ED Jr, Howards SS. Renal function after release of chronic unilateral hydronephrosis in man. Kidney Int 1975; 7:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12050/abstract/5\">",
"      Fr&oslash;kiaer J, Marples D, Knepper MA, Nielsen S. Bilateral ureteral obstruction downregulates expression of vasopressin-sensitive AQP-2 water channel in rat kidney. Am J Physiol 1996; 270:F657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12050/abstract/6\">",
"      Murer L, Addabbo F, Carmosino M, et al. Selective decrease in urinary aquaporin 2 and increase in prostaglandin E2 excretion is associated with postobstructive polyuria in human congenital hydronephrosis. J Am Soc Nephrol 2004; 15:2705.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7198 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-95F309B6B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_49_12050=[""].join("\n");
var outline_f11_49_12050=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5250160\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5250547\">",
"      URINE OUTPUT IN PARTIAL URINARY TRACT OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5250554\">",
"      POSTOBSTRUCTIVE DIURESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5250160\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24276?source=related_link\">",
"      Recovery of renal function after relief of urinary tract obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36456?source=related_link\">",
"      Urine output and residual renal function in renal failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_49_12051="Patient information: Vasculitis (The Basics)";
var content_f11_49_12051=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86015\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?43/43/44732\">",
"         Types of vasculitis",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?27/21/27986\">",
"         Patient information: Beh&ccedil;et&rsquo;s disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/25/21907\">",
"         Patient information: HIV/AIDS (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"./henoch-schonlein-purpura-iga-vasculitis-the-basics\">",
"         Patient information: Henoch-Sch&ouml;nlein purpura (IgA vasculitis) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/8/3201\">",
"         Patient information: Kawasaki disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/42/22178\">",
"         Patient information: Lupus (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/59/9138\">",
"         Patient information: Polyarteritis nodosa (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/24/42369\">",
"         Patient information: Polymyalgia rheumatica and giant cell arteritis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/31/16883\">",
"         Patient information: Rheumatoid arthritis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/57/37778\">",
"         Patient information: Steroid medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/40/27266\">",
"         Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/35/14900\">",
"         Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/22/44389\">",
"         Patient information: Vasculitis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Vasculitis (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1830249657\">",
"      <span class=\"h1\">",
"       What is vasculitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Vasculitis is inflammation in the blood vessels. It can damage the blood vessels and keep them from carrying blood to body parts that need it. Vasculitis can affect many different parts of the body.",
"     </p>",
"     <p>",
"      There are many different types of vasculitis (",
"      <a class=\"graphic graphic_table graphicRef85669 \" href=\"UTD.htm?43/43/44732\">",
"       table 1",
"      </a>",
"      ). Some are mild, and others are serious or even life-threatening.",
"     </p>",
"     <p>",
"      Vasculitis sometimes happens with another disease, such as lupus or rheumatoid arthritis. But vasculitis can also happen in people without other health problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1830249672\">",
"      <span class=\"h1\">",
"       What are the symptoms of vasculitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Tiredness",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Muscle and joint pain",
"       </li>",
"       <li>",
"        Lack of appetite &ndash; Some people with vasculitis lose weight without trying to.",
"       </li>",
"       <li>",
"        Belly pain",
"       </li>",
"       <li>",
"        Brown or dark-colored urine",
"       </li>",
"       <li>",
"        Numbness, weakness, or pain in the hands, feet, or other parts of the body",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1830249704\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Vasculitis symptoms can be a lot like symptoms of other diseases, so tests are important to help doctors learn the cause of symptoms. Tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood and urine tests",
"       </li>",
"       <li>",
"        Imaging tests &ndash; These can include X-rays or an MRI. Imaging tests create pictures of the inside of the body.",
"       </li>",
"       <li>",
"        Nerve conduction studies&nbsp;&ndash; These tests check whether nerves are carrying electrical signals the way they are supposed to. They can show nerve damage caused by vasculitis.",
"       </li>",
"       <li>",
"        Lung function tests &ndash; These tests measure how much air you can blow out of your lungs and how fast you can blow. They can show lung damage caused by vasculitis.",
"       </li>",
"       <li>",
"        A test called a &ldquo;biopsy&rdquo; &ndash; In this test, a doctor takes a small sample of tissue from an affected body part. Another doctor looks at the tissue under a microscope. This test can show signs of vasculitis and help doctors learn what type of vasculitis someone has.",
"       </li>",
"       <li>",
"        A test called an &ldquo;arteriogram&rdquo; &ndash; In this test, a doctor puts a thin tube into a blood vessel in a leg or arm. He or she moves the tube into blood vessels in the affected body part, such as the heart. Then the doctor injects a dye that shows up on an X-ray. The dye helps show changes in blood vessels caused by vasculitis.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1830249719\">",
"      <span class=\"h1\">",
"       How is vasculitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends on the type of vasculitis you have. Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Steroid medicines, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?27/36/28230?source=see_link\">",
"         prednisone",
"        </a>",
"        &ndash; These medicines can reduce or control inflammation. Because steroid medicines can cause serious side effects, doctors try to give them for as short a time as possible. Steroid medicines are not the same as the steroids athletes take to build muscle.",
"       </li>",
"       <li>",
"        Strong medicines that &ldquo;turn off&rdquo; the immune system, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/25/6550?source=see_link\">",
"         cyclophosphamide",
"        </a>",
"        (brand name: Procytox&reg;) - These medicines can be taken along with steroid medicines. Doctors use them to treat the most severe vasculitis.",
"       </li>",
"       <li>",
"        Other medicines that partly &ldquo;turn off&rdquo; the immune system, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?27/31/28149?source=see_link\">",
"         azathioprine",
"        </a>",
"        (sample brand names: Azasan&reg;, Imuran&reg;), and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?41/59/42934?source=see_link\">",
"         methotrexate",
"        </a>",
"        (Rheumatrex&reg;, Trexall&trade;) - These are not as strong as medicines like",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/25/6550?source=see_link\">",
"         cyclophosphamide",
"        </a>",
"        . Doctors use them to treat less severe types of vasculitis, or to switch patients off of cyclophosphamide after the worst of their symptoms are controlled.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      A type of vasculitis called &ldquo;hypersensitivity vasculitis&rdquo; is usually caused by a bad reaction to a medicine. If you get it, stopping the medicine might be the only treatment you need.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1830249734\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, talk to your doctor or nurse. Some medicines for vasculitis are not safe to take while pregnant. You might need to get symptoms under control or switch medicines before you try to get pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1830249749\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with vasculitis need regular exams and tests to check for problems the vasculitis can cause. It is important to take medicines exactly as prescribed and tell the doctor or nurse about any side effects. The right treatment can help you control the symptoms and stay as healthy as possible.",
"     </p>",
"     <p>",
"      Even though some types of vasculitis are very serious, doctors and nurses today know a lot about how to handle vasculitis, and many people with vasculitis live a long time. Sometimes, symptoms even go away for long periods of time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1830249764\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"./henoch-schonlein-purpura-iga-vasculitis-the-basics?source=see_link\">",
"       Patient information: Henoch-Sch&ouml;nlein purpura (IgA vasculitis) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/8/3201?source=see_link\">",
"       Patient information: Kawasaki disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=see_link\">",
"       Patient information: HIV/AIDS (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/42/22178?source=see_link\">",
"       Patient information: Lupus (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/59/9138?source=see_link\">",
"       Patient information: Polyarteritis nodosa (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/24/42369?source=see_link\">",
"       Patient information: Polymyalgia rheumatica and giant cell arteritis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=see_link\">",
"       Patient information: Rheumatoid arthritis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/57/37778?source=see_link\">",
"       Patient information: Steroid medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/21/27986?source=see_link\">",
"       Patient information: Beh&ccedil;et&rsquo;s disease (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/35/14900?source=see_link\">",
"       Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=see_link\">",
"       Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/22/44389?source=see_link\">",
"       Patient information: Vasculitis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/49/12051?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86015 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-57BF54AE18-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_49_12051=[""].join("\n");
var outline_f11_49_12051=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1830249657\">",
"      What is vasculitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1830249672\">",
"      What are the symptoms of vasculitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1830249704\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1830249719\">",
"      How is vasculitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1830249734\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1830249749\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1830249764\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86015\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/43/44732\">",
"      Types of vasculitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/21/27986?source=related_link\">",
"      Patient information: Beh&ccedil;et&rsquo;s disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=related_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=related_link\">",
"      Patient information: HIV/AIDS (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"./henoch-schonlein-purpura-iga-vasculitis-the-basics?source=related_link\">",
"      Patient information: Henoch-Sch&ouml;nlein purpura (IgA vasculitis) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/8/3201?source=related_link\">",
"      Patient information: Kawasaki disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/42/22178?source=related_link\">",
"      Patient information: Lupus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/35/14900?source=related_link\">",
"      Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/59/9138?source=related_link\">",
"      Patient information: Polyarteritis nodosa (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/24/42369?source=related_link\">",
"      Patient information: Polymyalgia rheumatica and giant cell arteritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=related_link\">",
"      Patient information: Rheumatoid arthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/57/37778?source=related_link\">",
"      Patient information: Steroid medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/22/44389?source=related_link\">",
"      Patient information: Vasculitis (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_49_12052="Fluocinolone (topical): Pediatric drug information";
var content_f11_49_12052=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluocinolone (topical): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?24/28/25029?source=see_link\">",
"    see \"Fluocinolone (topical): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/16/5380?source=see_link\">",
"    see \"Fluocinolone (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8097444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Capex&reg;;",
"     </li>",
"     <li>",
"      Derma-Smoothe/FS&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8097445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Capex&reg;;",
"     </li>",
"     <li>",
"      Derma-Smoothe/FS&reg;;",
"     </li>",
"     <li>",
"      Synalar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10501531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenal Corticosteroid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10503156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/28/25029?source=see_link\">",
"      see \"Fluocinolone (topical): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Children and Adults: Topical: Apply thin layer 2-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capex&trade; shampoo: Adults: Thoroughly wet hair and scalp; apply &le;1 ounce to scalp area; massage well; work into lather; allow to remain on scalp for 5 minutes; then rinse hair and scalp thoroughly; repeat daily until symptoms subside;",
"     <b>",
"      Note:",
"     </b>",
"     Once patient is symptom-free, once-weekly use usually keeps itching and flaking of dandruff from returning.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Derma-Smoothe/FS&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;2 years: Atopic dermatitis: Apply in a thin layer to moistened skin of affected area twice daily for &le;4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Atopic dermatitis: Apply a thin layer to affected area 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Scalp psoriasis: Thoroughly wet or dampen hair and scalp; apply to scalp in a thin layer, massage well; cover scalp with shower cap (supplied); leave for a minimum of 4 hours or overnight, then wash hair and rinse thoroughly",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8100716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as acetonide: 0.01% (15 g, 60 g); 0.025% (15 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, topical, as acetonide [body oil]: 0.01% (118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Derma-Smoothe/FS&reg;: 0.01% (120 mL) [contains isopropyl alcohol, peanut oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, topical, as acetonide [scalp oil]: 0.01% (118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Derma-Smoothe/FS&reg;: 0.01% (120 mL) [contains isopropyl alcohol, peanut oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as acetonide: 0.025% (15 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo, topical, as acetonide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capex&reg;: 0.01% (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical, as acetonide: 0.01% (60 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8097456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes shampoo",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10503157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply sparingly in a thin film; rub in lightly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capex&trade; shampoo: Shake well before use; do not bandage, wrap, or cover treated scalp area unless directed by physician; discard shampoo after 3 months (",
"     <b>",
"      Note:",
"     </b>",
"     Pharmacist must empty the contents of the 12 mg fluocinolone acetonide capsule into the shampoo base before dispensing to patient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Derma-Smoothe/FS&reg;: Do not apply to face or diaper area; avoid application to intertriginous areas (may increase local adverse effects)",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10501533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature in tightly closed container.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10503151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of susceptible inflammatory dermatosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capex&trade; shampoo: Adults: Treatment of seborrheic dermatitis of the scalp",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Derma-Smoothe/FS&reg;: Children &le;2 years: Moderate to severe atopic dermatitis (for use &le;4 weeks); Adults: Atopic dermatitis or psoriasis of the scalp",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8097421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fluocinolone may be confused with fluocinonide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8097489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Intracranial hypertension (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Telangiectasia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Acneiform eruptions, allergic contact dermatitis, burning, dryness, folliculitis, irritation, itching, hypertrichosis, hypopigmentation, miliaria, perioral dermatitis, skin atrophy, striae",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Cushing's syndrome, HPA axis suppression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Otic: Ear infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Herpes simplex, secondary infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10503152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluocinolone or any component; TB of skin; herpes (including varicella);",
"     <b>",
"      Note:",
"     </b>",
"     Contains peanut oil.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10503153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infants and small children may be more susceptible to adrenal axis suppression from topical corticosteroid therapy; systemic effects may occur when used on large areas of the body, denuded areas, for prolonged periods of time, or with an occlusive dressing. Derma-Smoothe/FS&reg; contains refined peanut oil; use with caution in patients with peanut hypersensitivity. Hypothalamic pituitary adrenal (HPA) axis suppression may occur; acute adrenal insufficiency may occur with abrupt withdrawal after long-term use or with stress; withdrawal or discontinuation should be done carefully; patients with HPA axis suppression may require doses of systemic glucocorticosteroids prior to, during, and after unusual stress (eg, surgery).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8097493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8097469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8097470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies. In general, the use of topical corticosteroids during pregnancy is not considered to have significant risk; however, intrauterine growth retardation in the infant has been reported (rare). The use of large amounts or for prolonged periods of time should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10501534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not well-defined topically; possesses anti-inflammatory, antiproliferative, and immunosuppressive properties",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10503155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Dependent on strength of preparation, amount applied, nature of skin at application site, vehicle, and use of occlusive dressing; increased in areas of skin damage, inflammation, or occlusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Throughout local skin; absorbed drug is distributed rapidly into muscle, liver, skin, intestines, and kidneys",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Primarily in skin; small amount absorbed into systemic circulation is primarily hepatic to inactive compounds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (primarily as glucuronide and sulfate, also as unconjugated products); feces (small amounts)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10501535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/16/5380?source=see_link\">",
"      see \"Fluocinolone (topical): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid contact with eyes; do not use for longer than directed; do not overuse; notify physician if condition being treated persists or worsens",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10503158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Considered a moderate-potency steroid (Derma-Smoothe/FS&reg; and Capex&trade; shampoo are considered to be low to medium potency); Derma-Smoothe/FS&reg; is made with 48% refined peanut oil, NF (peanut protein is &lt;0.5 ppm)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15987 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-8C00B56BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_49_12052=[""].join("\n");
var outline_f11_49_12052=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097444\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097445\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501531\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503156\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100716\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097456\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503157\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501533\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503151\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097421\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097489\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503152\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503153\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299349\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097493\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097469\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097470\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501534\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503155\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501535\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503158\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15987\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15987|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/18/29987?source=related_link\">",
"      Fluocinolone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/32/3587?source=related_link\">",
"      Fluocinolone (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/9/23699?source=related_link\">",
"      Fluocinolone (otic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/12/1220?source=related_link\">",
"      Fluocinolone (otic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/15/29938?source=related_link\">",
"      Fluocinolone (otic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/28/25029?source=related_link\">",
"      Fluocinolone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/16/5380?source=related_link\">",
"      Fluocinolone (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_49_12053="TTP-HUS: Recurrence after transplantation";
var content_f11_49_12053=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   TTP-HUS: Recurrence after transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/49/12053/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/49/12053/contributors\">",
"     Mohamed H Sayegh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/49/12053/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/49/12053/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/49/12053/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/49/12053/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/49/12053/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 19, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) describes acute syndromes with abnormalities in multiple systems. However, some evidence suggests that the two entities may be distinguished based upon the presence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    activity of the von Willebrand factor cleaving protease (ADAMTS13). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss recurrent TTP-HUS in renal transplant recipients. A discussion of TTP-HUS in non-renal transplant patients, such as bone marrow transplant recipients, is presented separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RECURRENT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported recurrence rate of HUS after renal transplantation is between 25 and 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. This may, however, represent an overestimate, since both acute vascular rejection and calcineurin inhibitor therapy can lead to vascular injury and a thrombotic microangiopathy indistinguishable from the primary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple clinical characteristics may be associated with recurrent HUS in the renal allograft. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a history of HUS due to nondiarrheal causes (non-shiga associated [NStx] HUS) may be at a much higher risk of recurrence after transplantation than those with HUS following an episode of diarrhea. A report of one center's experience in combination with a review of the literature found that 25 of 26 transplant recipients with recurrent HUS had a history of NStx HUS [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/5\">",
"       5",
"      </a>",
"      ]. Another single center study of 35 patients who received 50 allografts found that recurrence occurred in 10 of 17 adult onset cases (59 percent) and one of 18 (6 percent) with childhood HUS [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/3\">",
"       3",
"      </a>",
"      ]. Similar observations have been made in another study in children [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43849?source=see_link\">",
"       \"Atypical hemolytic uremic syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A meta-analysis of 159 grafts in 126 patients found that recurrent HUS was significantly associated with older age at onset of HUS, short duration between disease onset and end-stage renal disease or transplantation, use of living related donors, and, to a lesser degree, the administration of calcineurin inhibitors [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recurrent disease occurs in most patients with familial HUS [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/8,9\">",
"       8,9",
"      </a>",
"      ] which is usually due to mutations in some of the complement inhibitor genes [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43849?source=see_link\">",
"       \"Atypical hemolytic uremic syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Limited evidence suggests a lower recurrence rate among patients who had undergone nephrectomy. Using pooled data from several series, recurrence had reportedly occurred among 5 of 14 patients with nephrectomy versus 27 of 35 patients who had not undergone the procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Affected patients typically present with a microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. Graft loss has been reported in 10 to 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/2,5,12,13\">",
"     2,5,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall graft success may be diminished in patients with recurrent TTP-HUS. In a literature review of allograft recipients with a history of HUS, the one and five year allograft survival rates were 33 and 19 percent for those with recurrent disease, respectively, compared to 57 percent for patients without recurrent HUS [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/11\">",
"     11",
"    </a>",
"    ]. As mentioned above, recurrence is almost invariable in patients with some forms of familial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/8,9,14\">",
"     8,9,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two phases in the management of TTP-HUS in the transplant. The first phase is directed at prevention by the administration of low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It has also been suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and antilymphocyte serum (ALS) should be used with caution in these patients. A review of 114 patients with HUS (both recurrent and de novo) after organ transplantation found that two-thirds had been treated with cyclosporine [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/1\">",
"     1",
"    </a>",
"    ]. This observation, however, does not prove a cause-and-effect relationship.",
"   </p>",
"   <p>",
"    The second phase involves treatment of recurrent HUS. The dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    should be reduced by 50 percent at the first sign of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/1\">",
"     1",
"    </a>",
"    ]. Plasma infusions and plasma exchange, similar to that used for the primary disease, have been given with some apparent success in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/1,15-17\">",
"     1,15-17",
"    </a>",
"    ]. It is likely that the same considerations apply to thrombotic thrombocytopenic purpura, although the transplant experience in this disorder is extremely limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DE NOVO HUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;De novo HUS, developing in transplant recipients with a different primary renal disease, is a rare problem except for early",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    toxicity and acute vascular rejection as noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/1,18,19\">",
"     1,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients receiving OKT3 develop arterial and venous thrombi within the allograft, leading to loss of the graft [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/20\">",
"     20",
"    </a>",
"    ]. This complication is most likely to occur with high-dose OKT3 (10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    rather than the current recommendation of 5",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"   </p>",
"   <p>",
"    De novo HUS may be associated with a variety of other factors. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       Tacrolimus",
"      </a>",
"      (FK506) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/19,21-24\">",
"       19,21-24",
"      </a>",
"      ]. However, renal allograft recipients who develop TTP-HUS while taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      may have a high rate of graft salvage after switching to tacrolimus (13 of 16 in one report) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The combination of",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"        sirolimus",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"        cyclosporine",
"       </a>",
"       .",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17562?source=see_link\">",
"       \"Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       Valacyclovir",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HIV, parvovirus B19 (associated with red cell aplasia), and possibly other infections, including CMV [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/18,27-31\">",
"       18,27-31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibodies against the von Willebrand factor-cleaving metalloprotease ADAMTS13, which are responsible for most cases of idiopathic TTP [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mutations in complement receptors [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Antibody-mediated rejection [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An extensive discussion relating to the causes of TTP-HUS independent of renal transplantation can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients present with de novo disease localized to the allograft, while others have additional systemic manifestations, such as thrombocytopenia and hemolytic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/19\">",
"     19",
"    </a>",
"    ]. De novo localized disease appears to be associated with a better renal prognosis, with allograft loss and the required use of plasma exchange",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dialysis being less likely than that observed with systemic disease.",
"   </p>",
"   <p>",
"    Withdrawal of the suspect drug may lead to resolution of the de novo disease, with the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/4,35\">",
"     4,35",
"    </a>",
"    ]. The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    may also permit the thrombopathy to resolve [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/19\">",
"     19",
"    </a>",
"    ]. Success has also been reported with plasma exchange, intravenous immunoglobulin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/41/43669?source=see_link\">",
"     belatacept",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12053/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/1\">",
"      Agarwal A, Mauer SM, Matas AJ, Nath KA. Recurrent hemolytic uremic syndrome in an adult renal allograft recipient: current concepts and management. J Am Soc Nephrol 1995; 6:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/2\">",
"      Hebert D, Sibley RK, Mauer SM. Recurrence of hemolytic uremic syndrome in renal transplant recipients. Kidney Int Suppl 1986; 19:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/3\">",
"      Artz MA, Steenbergen EJ, Hoitsma AJ, et al. Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections. Transplantation 2003; 76:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/4\">",
"      Oyen O, Str&oslash;m EH, Midtvedt K, et al. Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome. Am J Transplant 2006; 6:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/5\">",
"      Miller RB, Burke BA, Schmidt WJ, et al. Recurrence of haemolytic-uraemic syndrome in renal transplants: a single-centre report. Nephrol Dial Transplant 1997; 12:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/6\">",
"      Quan A, Sullivan EK, Alexander SR. Recurrence of hemolytic uremic syndrome after renal transplantation in children: a report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation 2001; 72:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/7\">",
"      Ducloux D, Rebibou JM, Semhoun-Ducloux S, et al. Recurrence of hemolytic-uremic syndrome in renal transplant recipients: a meta-analysis. Transplantation 1998; 65:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/8\">",
"      Kaplan BS, Papadimitriou M, Brezin JH, et al. Renal transplantation in adults with autosomal recessive inheritance of hemolytic uremic syndrome. Am J Kidney Dis 1997; 30:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/9\">",
"      Remuzzi G, Ruggenenti P, Codazzi D, et al. Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet 2002; 359:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/10\">",
"      Caprioli J, Bettinaglio P, Zipfel PF, et al. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 2001; 12:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/11\">",
"      Lahlou A, Lang P, Charpentier B, et al. Hemolytic uremic syndrome. Recurrence after renal transplantation. Groupe Coop&eacute;ratif de l'Ile-de-France (GCIF). Medicine (Baltimore) 2000; 79:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/12\">",
"      Kotanko P, Pusey CD, Levy JB. Recurrent glomerulonephritis following renal transplantation. Transplantation 1997; 63:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/13\">",
"      Cameron JS. Glomerulonephritis in renal transplants. Transplantation 1982; 34:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/14\">",
"      Ruggenenti P. Post-transplant hemolytic-uremic syndrome. Kidney Int 2002; 62:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/15\">",
"      Springate J, Fildes R, Anthone S, et al. Recurrent hemolytic syndrome after renal transplantation. Transplant Proc 1988; 20:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/16\">",
"      Stevenson JA, Dumke A, Glassock RJ, et al. Thrombotic microangiopathy: recurrence following renal transplant and response to plasma infusion. Am J Nephrol 1982; 2:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/17\">",
"      Zarifian A, Meleg-Smith S, O'donovan R, et al. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 1999; 55:2457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/18\">",
"      Miller BW, Hmiel SP, Schnitzler MA, Brennan DC. Cyclosporine as cause of thrombotic microangiopathy after renal transplantation. Am J Kidney Dis 1997; 29:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/19\">",
"      Schwimmer J, Nadasdy TA, Spitalnik PF, et al. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis 2003; 41:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/20\">",
"      Abramowicz D, Pradier O, Marchant A, et al. Induction of thromboses within renal grafts by high-dose prophylactic OKT3. Lancet 1992; 339:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/21\">",
"      Holman MJ, Gonwa TA, Cooper B, et al. FK506-associated thrombotic thrombocytopenic purpura. Transplantation 1993; 55:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/22\">",
"      Trimarchi HM, Truong LD, Brennan S, et al. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. Transplantation 1999; 67:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/23\">",
"      Pham PT, Peng A, Wilkinson AH, et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kidney Dis 2000; 36:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/24\">",
"      Kiykim AA, Ozer C, Yildiz A, et al. Development of transplant renal artery thrombosis and signs of haemolytic-uraemic syndrome following the change from cyclosporin to tacrolimus in a renal transplant patient. Nephrol Dial Transplant 2004; 19:2653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/25\">",
"      Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis 1998; 177:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/26\">",
"      Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore) 1997; 76:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/27\">",
"      Frem GJ, Rennke HG, Sayegh MH. Late renal allograft failure secondary to thrombotic microangiopathy-human immunodeficiency virus nephropathy. J Am Soc Nephrol 1994; 4:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/28\">",
"      Tschuchnigg M, Bradstock KF, Koutts J, et al. A case of thrombotic thrombocytopenic purpura following allogeneic bone marrow transplantation. Bone Marrow Transplant 1990; 5:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/29\">",
"      Jeejeebhoy FM, Zaltzman JS. Thrombotic microangiopathy in association with cytomegalovirus infection in a renal transplant patient: a new treatment strategy. Transplantation 1998; 65:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/30\">",
"      Hochstetler LA, Flanigan MJ, Lager DJ. Transplant-associated thrombotic microangiopathy: the role of IgG administration as initial therapy. Am J Kidney Dis 1994; 23:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/31\">",
"      Murer L, Zacchello G, Bianchi D, et al. Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation. J Am Soc Nephrol 2000; 11:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/32\">",
"      Pham PT, Danovitch GM, Wilkinson AH, et al. Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient. Transplantation 2002; 74:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/33\">",
"      Le Quintrec M, Lionet A, Kamar N, et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 2008; 8:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/34\">",
"      Satoskar AA, Pelletier R, Adams P, et al. De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection. Am J Transplant 2010; 10:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/35\">",
"      Bren A, Pajek J, Grego K, et al. Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy. Transplant Proc 2005; 37:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12053/abstract/36\">",
"      Ashman N, Chapagain A, Dobbie H, et al. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. Am J Transplant 2009; 9:424.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7350 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-A58E39C754-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_49_12053=[""].join("\n");
var outline_f11_49_12053=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RECURRENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DE NOVO HUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43849?source=related_link\">",
"      Atypical hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17562?source=related_link\">",
"      Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_49_12054="Citalopram: Patient drug information";
var content_f11_49_12054=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Citalopram: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     see \"Citalopram: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/16/38152?source=see_link\">",
"     see \"Citalopram: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F151983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      CeleXA&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F151984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Citalopram&reg;;",
"     </li>",
"     <li>",
"      Auro-Citalopram;",
"     </li>",
"     <li>",
"      Ava-Citalopram;",
"     </li>",
"     <li>",
"      Celexa&reg;;",
"     </li>",
"     <li>",
"      Citalopram-Odan;",
"     </li>",
"     <li>",
"      CO Citalopram;",
"     </li>",
"     <li>",
"      CTP 30;",
"     </li>",
"     <li>",
"      Dom-Citalopram;",
"     </li>",
"     <li>",
"      JAMP-Citalopram;",
"     </li>",
"     <li>",
"      Manda-Citalopram;",
"     </li>",
"     <li>",
"      Mint-Citalopram;",
"     </li>",
"     <li>",
"      Mylan-Citalopram;",
"     </li>",
"     <li>",
"      PHL-Citalopram;",
"     </li>",
"     <li>",
"      PMS-Citalopram;",
"     </li>",
"     <li>",
"      Q-Citalopram;",
"     </li>",
"     <li>",
"      RAN&trade;-Citalo;",
"     </li>",
"     <li>",
"      ratio-Citalopram;",
"     </li>",
"     <li>",
"      Riva-Citalopram;",
"     </li>",
"     <li>",
"      Sandoz-Citalopram;",
"     </li>",
"     <li>",
"      Septa-Citalopram;",
"     </li>",
"     <li>",
"      Teva-Citalopram",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10011277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called serotonin syndrome may happen. The risk may be greater if you take this drug with certain other drugs. Call your doctor right away if you have dizziness, very bad headache, agitation, hallucinations, fever, fast heartbeat, a heartbeat that does not feel normal, flushing, seizures, shakiness, sweating a lot, change in balance, change in thinking clearly and with logic, very bad upset stomach and throwing up, or very bad loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691994",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat obsessive-compulsive problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701816",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to citalopram or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4232023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking any of these drugs: Linezolid or methylene blue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697573",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Make sure you have the right drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called serotonin syndrome may happen. The risk may be greater if you take this drug with certain other drugs. Call your doctor right away if you have dizziness, very bad headache, agitation, hallucinations, fever, fast heartbeat, a heartbeat that does not feel normal, flushing, seizures, shakiness, sweating a lot, change in balance, change in thinking clearly and with logic, very bad upset stomach and throwing up, or very bad loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bleeding problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a heart problem called congenital QT syndrome, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a stroke, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697078",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking any natural products, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Agitation, twitching, sweating, or muscle stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12225 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-218.28.111.102-5CC63B1F68-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_49_12054=[""].join("\n");
var outline_f11_49_12054=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151983\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151984\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011277\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011279\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011278\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011283\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011284\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011286\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011281\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011282\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011287\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011288\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=related_link\">",
"      Citalopram: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/16/38152?source=related_link\">",
"      Citalopram: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_49_12055="Congenital anomalies of the ear";
var content_f11_49_12055=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Congenital anomalies of the ear",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/49/12055/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/49/12055/contributors\">",
"     Glenn C Isaacson, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/49/12055/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/49/12055/contributors\">",
"     Ellen M Friedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/49/12055/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/49/12055/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/49/12055/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/49/12055/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital anomalies are the product of errors in embryogenesis (malformations) or the result of intrauterine events that affect embryonic and fetal growth (deformations and disruptions) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/1\">",
"     1",
"    </a>",
"    ]. The more complex the formation of a structure, the more opportunities for malformation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19574?source=see_link\">",
"     \"Principles of teratology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The formation of the ear involves fusion of ectoderm, endoderm, and mesoderm. Defects in formation may lead to a wide variety of dysfunctional or malformed structures. The embryology, clinical features, and management of congenital anomalies of the ear are reviewed here. Congenital anomalies of the upper respiratory and gastrointestinal tracts are discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EMBRYOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Outer ear",
"    </span>",
"    &nbsp;&mdash;&nbsp;The auricle or pinna is formed from the fusion of six raised soft tissue swellings (hillocks) on the surface of the embryo. Three of these hillocks are derived from the first branchial arch (Meckel) and three from the second branchial arch (Reichert) during the fifth and sixth weeks of intrauterine life. Growth of the fused tissues, guided by the pull of the intrinsic muscles of the ear, creates the folds of the helix, antihelix, and tragus (",
"    <a class=\"graphic graphic_figure graphicRef80743 \" href=\"UTD.htm?27/47/28404\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The ear canal is formed from an invagination of surface epithelium in the fifth week of intrauterine life. This solid core of cells meets a similar evagination from the pharynx, trapping a layer of mesothelium in between (",
"    <a class=\"graphic graphic_figure graphicRef67764 \" href=\"UTD.htm?28/6/28770\">",
"     figure 2",
"    </a>",
"    ). Fusion of these cells at the juncture results in the formation of the three layers of the tympanic membrane (",
"    <a class=\"graphic graphic_figure graphicRef74065 \" href=\"UTD.htm?30/28/31173\">",
"     figure 3",
"    </a>",
"    ). Recanalization of the external ear canal occurs in the second trimester and is complete at approximately 28 weeks' gestation; vernix-like material is left behind [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The external auditory meatus is formed from an invagination of squamous epithelium from the first branchial cleft. This solid core of tissue recanalizes at the beginning of the third trimester.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Middle ear",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ossicles are formed by condensation of mesenchyme derived from the first and second branchial arches. Cartilage develops and gradually is replaced by bone in the second and third trimesters (",
"    <a class=\"graphic graphic_picture graphicRef75999 \" href=\"UTD.htm?27/41/28306\">",
"     picture 1",
"    </a>",
"    ). The ossicles are near adult size and adult ossification at the time of birth. Cartilage remains only at the articulations.",
"   </p>",
"   <p>",
"    The cavity of the middle ear forms when endoderm evaginating from the first pharyngeal pouch invades the mesoderm of the middle ear. This pouch narrows to form the lining of the eustachian tube near the nasopharynx and spawns fingerlike projections that surround the developing ossicles. The lateral-most projection of endoderm creates the inner layer of the tympanic membrane.",
"   </p>",
"   <p>",
"    At birth, the middle ear is narrow and contains residual mesenchyme and amniotic fluid. Within minutes of birth and spontaneous breathing, air enters the eustachian tube, displacing amniotic fluid to create a pneumatized cavity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Inner ear",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cochlea and vestibular system are derived from epithelium that migrates deep from within the embryonic surface early in development. This epithelium forms a fluid-filled cyst called the otic vesicle. The otic vesicle folds, spirals, and elongates to form the membranous labyrinth (",
"    <a class=\"graphic graphic_picture graphicRef75108 \" href=\"UTD.htm?35/10/36001\">",
"     picture 2",
"    </a>",
"    ). Neural cells arising in the eighth cranial nerve invade the labyrinth. By the end of the second trimester, the inner ear is developed sufficiently to transduce vibratory energy into neural impulses that are transmitted to the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     OUTER EAR MALFORMATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Microtia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incomplete development and growth of the pinna can lead to a small, deformed, or absent pinna. Microtia and anotia occur in one to three per 10,000 births [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/4\">",
"     4",
"    </a>",
"    ]. They occur more frequently in boys, at increased altitude, with increasing birth order, in infants of diabetic mothers, and infants with prenatal exposure to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/33/19991?source=see_link\">",
"     isotretinoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/42/42664?source=see_link\">",
"     thalidomide",
"    </a>",
"    , alcohol, or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"     mycophenolate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/4-8\">",
"     4-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In unilateral cases, the right side is affected more commonly than the left. Microtia and anotia may occur in isolation or in association with other malformations, including facial clefts, cardiac defects, limb anomalies, renal anomalies, and holoprosencephaly [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/4,9\">",
"     4,9",
"    </a>",
"    ]. Genetic factors appear to play an important role in isolated, nonsyndromic cases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Normal",
"    <span class=\"nowrap\">",
"     (right/left)",
"    </span>",
"    ears vary in length by no more than 10 percent in large anthropometric studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/11\">",
"     11",
"    </a>",
"    ]. In the Marx classification system, type I microtia is characterized as a generally well-formed, perceptibly smaller auricle. In type II microtia, the pinna is malformed and 50 to 66 percent smaller than the contralateral pinna. In grade III microtia, the auricle is severely malformed and usually exhibits a peanut shape [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one series of 145 cases, more than two-thirds of the cases were sporadic, and approximately one-third were familial [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/9\">",
"     9",
"    </a>",
"    ]. Among the familial cases, autosomal dominant inheritance was most common, but cases with autosomal recessive and multifactorial inheritance were also noted.",
"   </p>",
"   <p>",
"    Evaluation of infants with microtia and anotia should include a careful examination for associated defects; audiologic testing; and imaging to diagnose the possible presence of associated external auditory canal, middle, and inner ear abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consultations with a clinical geneticist, an otolaryngologist, and an experienced plastic surgeon are warranted in the neonatal period. Although intervention for unilateral defects seldom is undertaken until the child reaches four to six years of age, these consultations are reassuring to parents and families.",
"   </p>",
"   <p>",
"    Long-term management also may include audiology, speech therapy, and educational intervention. Amplification devices are beneficial for children with bilateral hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29927?source=see_link\">",
"     \"Treatment of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Minor abnormality of the pinna may not require correction. When the pinna is grossly deformed or absent, reconstruction often is warranted for cosmetic reasons. Most repairs are undertaken when the child is four to six years of age, before the child starts primary school, and after the pinna has reached 80 percent of its adult size.",
"   </p>",
"   <p>",
"    Microtia repair is complex and often requires several stages [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/15\">",
"     15",
"    </a>",
"    ]. A cartilage framework, usually derived from costal cartilage, is created and anchored beneath the skin of the mastoid area. Once it is well attached to surface skin, a post-auricular crease is created in a second operation. Additional procedures often are employed for \"fine-tuning.\" Even in the best hands, the complex structure of the external ear is difficult to duplicate, and cosmetic results vary widely. The placement of a prosthetic auricle anchored with an osteointegrated peg remains an option [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lop or outstanding ear",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protruding ears usually result from incomplete formation of the antihelical fold (",
"    <a class=\"graphic graphic_picture graphicRef59636 \" href=\"UTD.htm?19/32/19971\">",
"     picture 3",
"    </a>",
"    ). This abnormality has no functional significance. However, children with protruding ears sometimes are ridiculed by their peers. Otoplasty usually is performed when the child is four to six years of age. The most common procedures involve the excision of skin from the posterior surface of the auricle and the placement of permanent sutures to reposition the ear and create an antihelical fold [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Preauricular pits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preauricular pits, which are small indentations located anterior to the helix and superior to the tragus of the ear (bilateral in 25 to 50 percent of cases), represent the most common fusion abnormality of the auricular hillocks (",
"    <a class=\"graphic graphic_picture graphicRef75371 \" href=\"UTD.htm?31/1/31775\">",
"     picture 4",
"    </a>",
"    ). They are present in 1 percent of white, 5 percent of black, and 10 percent of Asian children and occur with increased frequency in some families [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/18\">",
"     18",
"    </a>",
"    ]. Associated congenital anomalies occur in approximately one-third of the sporadic cases and none of the familial ones [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/19\">",
"     19",
"    </a>",
"    ]. Children with preauricular pits or tags are at five times the risk of the general population for permanent hearing impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants with preauricular pits should have formal audiologic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/20\">",
"     20",
"    </a>",
"    ]. Preauricular pits may be the first indication of branchio-oto-renal syndrome (BOR), the most common inherited syndrome causing hearing loss (",
"    <a class=\"graphic graphic_picture graphicRef81273 \" href=\"UTD.htm?29/30/30177\">",
"     picture 5",
"    </a>",
"    ). BOR is an autosomal dominant syndrome characterized by sensorineural hearing loss, preauricular pits, branchial cysts, malformed ears, and renal anomalies, including renal dysplasia and bifid renal pelvises [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10935?source=see_link&amp;anchor=H12#H12\">",
"     \"Renal hypoplasia\", section on 'Branchio-oto-renal syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of renal anomalies in patients with isolated preauricular pits does not significantly differ from that in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Association with renal anomalies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Preauricular pits do not require surgery unless they become repeatedly infected or discharge squamous material (",
"    <a class=\"graphic graphic_picture graphicRef75371 \" href=\"UTD.htm?31/1/31775\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/18\">",
"     18",
"    </a>",
"    ]. If surgery is performed, it should include excision of the pit, the squamous-lined cyst usually present beneath the skin (",
"    <a class=\"graphic graphic_picture graphicRef65609 \" href=\"UTD.htm?7/7/7282\">",
"     picture 6",
"    </a>",
"    ), and the cartilage at the root of the helix en bloc to avoid recurrence (",
"    <a class=\"graphic graphic_picture graphicRef54441 \" href=\"UTD.htm?32/26/33199\">",
"     picture 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Accessory auricular appendage/preauricular tag",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accessory hillocks composed of skin, subcutaneous fat,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cartilage may occur near the auricle or anywhere along the anterior border of the sternocleidomastoid muscle (",
"    <a class=\"graphic graphic_picture graphicRef66027 \" href=\"UTD.htm?36/33/37407\">",
"     picture 8",
"    </a>",
"    ). These accessory auricular appendages are called preauricular tags when they are present in the preauricular area. Such appendages usually are removed in childhood for cosmetic purposes.",
"   </p>",
"   <p>",
"    Children with accessory auricular appendages may have associated unilateral hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/20\">",
"     20",
"    </a>",
"    ]. They should have complete audiologic testing, preferably at birth. Accessory auricular appendages, particularly at the tragus, may appear as part of the oculo-auriculo-vertebral spectrum (also called Goldenhar syndrome, hemifacial microsomia, facio-auriculo-vertebral spectrum, and first and second branchial arch syndrome). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/15/250?source=see_link&amp;anchor=H2#H2\">",
"     \"Syndromes with craniofacial abnormalities\", section on 'Craniofacial microsomia (CFM)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Aural atresia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure of complete invagination of the external auditory canal results in an absent or stenotic ear canal and improper formation of the eardrum. Failure of recanalization results in membranous stenosis or atresia (",
"    <a class=\"graphic graphic_picture graphicRef80506 \" href=\"UTD.htm?34/19/35135\">",
"     picture 9",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Formation of the ossicles occurs at the same time as does invagination of the first branchial cleft. Associated abnormalities of the ossicles, particularly fusion of the ossicles to each other or to atretic bone in the auditory canal, occur commonly in children with aural atresia.",
"   </p>",
"   <p>",
"    Children who have unilateral aural atresia seldom require surgery if the pinna is well formed and the contralateral ear has normal hearing [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/25\">",
"     25",
"    </a>",
"    ]. Such children will not benefit from a bone-conduction hearing aid, since they have normal hearing perception and bone-conduction hearing aids do not help to localize sound. Amplification is important if the child has hearing loss in the contralateral ear.",
"   </p>",
"   <p>",
"    Many children with aural atresia have normal middle ears and can develop acute otitis media (AOM). Children with aural atresia should be treated with antibiotics if AOM is suspected clinically, because the diagnosis cannot be confirmed through otoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/14,26\">",
"     14,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=see_link\">",
"     \"Acute otitis media in children: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with unrepaired aural atresia also have a risk of developing middle ear cholesteatoma. Persistent ear pain or fever may be the only clues to this condition, which is diagnosed with computed tomography (CT). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42808?source=see_link\">",
"     \"Cholesteatoma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bilateral aural atresia is associated with a maximal conductive hearing loss (approximately 60 dB) and requires early intervention. Children with bilateral aural atresia should be fit with a bone-conduction hearing aid within weeks of birth to assist with early language acquisition [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/27\">",
"     27",
"    </a>",
"    ]. Bone-anchored hearing aids (BAHA) have gained greater acceptance as an alternative for hearing habilitation in children with bilateral aural atresia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29927?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of hearing impairment in children\", section on 'Bone conduction hearing devices'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery to correct aural atresia usually is performed toward the end of the first decade of life, when substantial mastoid development has occurred. Surgery entails the creation of a new ear canal and ear drum, providing a skin lining for the canal and drum, and mobilizing or repositioning the ossicles to allow transmission of sound. Surgery is more likely to be successful if extensive pneumatization of the mastoid air cells is present and the stapes is mobile. One of the major risks of this surgery is injury to the facial nerve or the dura of the middle cranial fossa. Thus, the procedure should be performed by an experienced otologist and with electrophysiologic facial nerve monitoring. The new ear canal often requires cleaning and care for life [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/29\">",
"     29",
"    </a>",
"    ]. The bone-anchored hearing aid is an alternative for patients who are not candidates for aural atresiaplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/30\">",
"     30",
"    </a>",
"    ]. Another option includes conventional hearing aids and glue-on prosthetic auricles (the former to address hearing loss and the latter for cosmetic purposes).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MIDDLE EAR MALFORMATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital malformations of the ossicles may cause conductive hearing loss. Ossicular and other middle ear malformations occur as part of syndromes (eg, Treacher-Collins, branchio-oto-renal, Stickler, Shprintzen, or Beckwith-Wiedemann) and occasionally as isolated events.",
"   </p>",
"   <p>",
"    The most common abnormalities of the ossicles are fixation of the malleus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    incus, incudostapedial discontinuity, and stapes fixation. Each of these abnormalities is surgically correctable; correction of stapes fixation is most likely to fail because of the delicate attachment of the stapes to the inner ear [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     INNER EAR MALFORMATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cochlea arises from a cystic invagination of surface epithelium (the otocyst) that pulls away from the vestibular portion of the inner ear during the first trimester and forms an elongating spiral. Failure of development along this pathway results in the Michel and Mondini anomalies, which can be detected with high-resolution CT [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Michel malformation occurs when the labyrinth is absent or reduced to a single cystic cavity. The Mondini malformation is present when cochlear growth is arrested at less than one complete turn (2.75 turns is normal) (",
"    <a class=\"graphic graphic_picture graphicRef62888 \" href=\"UTD.htm?9/32/9728\">",
"     picture 10",
"    </a>",
"    ). It is associated with complete deafness and vestibular malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Minor abnormalities in the labyrinthine structure also can result in partial or progressive hearing loss. The large vestibular aqueduct syndrome is one of the better known; it may affect one or both ears (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77374 \" href=\"UTD.htm?31/22/32111\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The hearing loss in children with large vestibular aqueduct syndrome may be sensorineural or mixed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/36\">",
"     36",
"    </a>",
"    ]. Some patients have normal hearing at birth, followed by progressive or fluctuating hearing loss. Sudden hearing loss may occur spontaneously or after minor head trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ASSOCIATION WITH RENAL ANOMALIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;External ear malformations and renal anomalies occur in several multiple congenital anomaly syndromes (eg, branchio-oto-renal syndrome, CHARGE association, Townes-Brocks syndrome, Nager syndrome, Miller syndrome, and diabetic embryopathy). In addition, children with external ear anomalies, particularly preauricular pits and cup ears, have a slightly increased risk of renal anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective study, 108 out of 17,286 infants born at a single medical center during a four-year period had isolated preauricular tags or pits [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/22\">",
"     22",
"    </a>",
"    ]. The infants were examined by a geneticist to confirm the absence of other congenital anomalies and underwent renal ultrasonography at one to three months of age. Their ultrasonography findings were compared with those of 95 healthy infants who underwent ultrasonography on the second day of life. The prevalence of renal abnormalities was similar between groups (2.2 percent and 3.1 percent in cases and controls, respectively). The abnormalities included mild pyelectasis (in two cases and three controls) and renal calculus (in one control). The authors conclude that renal ultrasonography is not indicated in infants with isolated preauricular pits or tags.",
"   </p>",
"   <p>",
"    The characteristics of children with coexistent ear and renal anomalies were described in a retrospective analysis of children who underwent clinical genetics evaluation for ear anomaly [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/40\">",
"     40",
"    </a>",
"    ]. Ear anomalies were defined as preauricular pits or tags, microtia, anotia, cup, lop, or other dysplastic ear. Renal anomalies were defined as unilateral or bilateral renal agenesis, hypoplasia, crossed ectopia, horseshoe, pelvic or cystic kidney, hydronephrosis, duplicated ureters, megaureter, or vesicoureteric reflux. Renal ultrasound was performed in 42 children; 12 children (29 percent) had renal anomalies; 11 of these children (92 percent) were diagnosed with a multiple congenital anomaly syndrome (MCA). Only one of nine children with isolated ear anomalies had renal anomalies.",
"   </p>",
"   <p>",
"    We suggest that renal ultrasound be performed in children with ear anomaly accompanied by any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Other malformations or dysmorphic features",
"     </li>",
"     <li>",
"      Family history of deafness or auricular or renal malformations",
"     </li>",
"     <li>",
"      Maternal history of gestational diabetes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the authors of the above study suggest that renal ultrasound be performed in children with isolated preauricular pit or cup ear [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12055/abstract/40\">",
"     40",
"    </a>",
"    ]. However, this recommendation is controversial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital outer ear anomalies include microtia, lop (outstanding, protruding) ear (",
"      <a class=\"graphic graphic_picture graphicRef59636 \" href=\"UTD.htm?19/32/19971\">",
"       picture 3",
"      </a>",
"      ), preauricular pits (",
"      <a class=\"graphic graphic_picture graphicRef75371 \" href=\"UTD.htm?31/1/31775\">",
"       picture 4",
"      </a>",
"      ), accessory auricular",
"      <span class=\"nowrap\">",
"       appendages/preauricular",
"      </span>",
"      tags (",
"      <a class=\"graphic graphic_picture graphicRef66027 \" href=\"UTD.htm?36/33/37407\">",
"       picture 8",
"      </a>",
"      ), and aural atresia (",
"      <a class=\"graphic graphic_picture graphicRef80506 \" href=\"UTD.htm?34/19/35135\">",
"       picture 9",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Outer ear malformations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Congenital middle ear anomalies include malformations of the ossicles (eg, fixation or incudostapedial discontinuity) and may result in conductive hearing loss. Ossicular malformations may occur as part of a syndrome or in isolation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Middle ear malformations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Congenital inner ear anomalies include the Michel and Mondini malformations, and the large vestibular aqueduct syndrome. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Inner ear malformations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      External ear malformations and renal anomalies occur in several multiple congenital anomaly syndromes. In addition, children with isolated ear anomalies may have a slightly increased risk of renal anomalies. We suggest that renal ultrasonography be performed in children with ear anomaly and any of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Other malformations or dysmorphic features",
"     </li>",
"     <li>",
"      Family history of deafness or auricular or renal malformations",
"     </li>",
"     <li>",
"      Maternal history of gestational diabetes",
"      <br/>",
"      <br/>",
"      (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Association with renal anomalies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Jones KL. Dysmorphology approach and classification. In: Smith's recognizable patterns of human malformation, 6th ed, Elsevier Saunders, Philadelphia 2006. p.1.",
"    </li>",
"    <li>",
"     Donaldson JA, Anson BJ. Surgical anatomy of the temporal bone. In: Surgical anatomy of the temporal bone, 4th ed, Donaldson JA, et al (Eds), Raven Press, New York 1992. p.19.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/3\">",
"      Isaacson G. Antenatal diagnosis of congenital deafness. Ann Otol Rhinol Laryngol 1988; 97:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/4\">",
"      Harris J, K&auml;ll&eacute;n B, Robert E. The epidemiology of anotia and microtia. J Med Genet 1996; 33:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/5\">",
"      Castilla EE, Lopez-Camelo JS, Campa&ntilde;a H. Altitude as a risk factor for congenital anomalies. Am J Med Genet 1999; 86:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/6\">",
"      Ewart-Toland A, Yankowitz J, Winder A, et al. Oculoauriculovertebral abnormalities in children of diabetic mothers. Am J Med Genet 2000; 90:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/7\">",
"      Ang GS, Simpson SA, Reddy AR. Mycophenolate mofetil embryopathy may be dose and timing dependent. Am J Med Genet A 2008; 146A:1963.",
"     </a>",
"    </li>",
"    <li>",
"     Microtia-anotia. In: Online Mendelian Inheritance in Man. file://www.ncbi.nlm.nih.gov/omim (Accessed on October 06, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/9\">",
"      Llano-Rivas I, Gonz&aacute;lez-del Angel A, del Castillo V, et al. Microtia: a clinical and genetic study at the National Institute of Pediatrics in Mexico City. Arch Med Res 1999; 30:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/10\">",
"      Artunduaga MA, Quintanilla-Dieck Mde L, Greenway S, et al. A classic twin study of external ear malformations, including microtia. N Engl J Med 2009; 361:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/11\">",
"      Ferrario VF, Sforza C, Ciusa V, et al. Morphometry of the normal human ear: a cross-sectional study from adolescence to mid-adulthood. J Craniofac Genet Dev Biol 1999; 19:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/12\">",
"      Ishimoto S, Ito K, Yamasoba T, et al. Correlation between microtia and temporal bone malformation evaluated using grading systems. Arch Otolaryngol Head Neck Surg 2005; 131:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/13\">",
"      Calzolari F, Garani G, Sensi A, Martini A. Clinical and radiological evaluation in children with microtia. Br J Audiol 1999; 33:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/14\">",
"      Eavey RD. Ear malformations. What a pediatrician can do to assist with auricular reconstruction. Pediatr Clin North Am 1996; 43:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/15\">",
"      Brent B. Technical advances in ear reconstruction with autogenous rib cartilage grafts: personal experience with 1200 cases. Plast Reconstr Surg 1999; 104:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/16\">",
"      Wilkes GH, Wolfaardt JF. Osseointegrated alloplastic versus autogenous ear reconstruction: criteria for treatment selection. Plast Reconstr Surg 1994; 93:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/17\">",
"      Lee D, Bluestone CD. The Becker technique for otoplasty: modified and revisited with long-term outcomes. Laryngoscope 2000; 110:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/18\">",
"      Scheinfeld NS, Silverberg NB, Weinberg JM, Nozad V. The preauricular sinus: a review of its clinical presentation, treatment, and associations. Pediatr Dermatol 2004; 21:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/19\">",
"      Meggyessy V, M&eacute;hes K. Preauricular pits in Hungary: epidemiologic and clinical observations. J Craniofac Genet Dev Biol 1982; 2:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/20\">",
"      Roth DA, Hildesheimer M, Bardenstein S, et al. Preauricular skin tags and ear pits are associated with permanent hearing impairment in newborns. Pediatrics 2008; 122:e884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/21\">",
"      Bellini C, Piaggio G, Massocco D, et al. Branchio-Oto-renal syndrome: a report on nine family groups. Am J Kidney Dis 2001; 37:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/22\">",
"      Kugelman A, Tubi A, Bader D, et al. Pre-auricular tags and pits in the newborn: the role of renal ultrasonography. J Pediatr 2002; 141:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/23\">",
"      Huang XY, Tay GS, Wansaicheong GK, Low WK. Preauricular sinus: clinical course and associations. Arch Otolaryngol Head Neck Surg 2007; 133:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/24\">",
"      Prasad S, Grundfast K, Milmoe G. Management of congenital preauricular pit and sinus tract in children. Laryngoscope 1990; 100:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/25\">",
"      Trigg DJ, Applebaum EL. Indications for the surgical repair of unilateral aural atresia in children. Am J Otol 1998; 19:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/26\">",
"      Brent B. The pediatrician's role in caring for patients with congenital microtia and atresia. Pediatr Ann 1999; 28:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/27\">",
"      B&eacute;jar-Solar I, Rosete M, de Jesus Madrazo M, Baltierra C. Percutaneous bone-anchored hearing aids at a pediatric institution. Otolaryngol Head Neck Surg 2000; 122:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/28\">",
"      Verhagen CV, Hol MK, Coppens-Schellekens W, et al. The Baha Softband. A new treatment for young children with bilateral congenital aural atresia. Int J Pediatr Otorhinolaryngol 2008; 72:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/29\">",
"      Lambert PR. Congenital aural atresia: stability of surgical results. Laryngoscope 1998; 108:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/30\">",
"      Yellon RF. Atresiaplasty versus BAHA for congenital aural atresia. Laryngoscope 2011; 121:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/31\">",
"      Briggs RJ, Luxford WM. Correction of conductive hearing loss in children. Otolaryngol Clin North Am 1994; 27:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/32\">",
"      Jackler RK, Luxford WM, House WF. Congenital malformations of the inner ear: a classification based on embryogenesis. Laryngoscope 1987; 97:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/33\">",
"      Phelps PD. Mondini and the dysplastic lateral semi-circular canal. ORL J Otorhinolaryngol Relat Spec 1994; 56:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/34\">",
"      Levenson MJ, Parisier SC, Jacobs M, Edelstein DR. The large vestibular aqueduct syndrome in children. A review of 12 cases and the description of a new clinical entity. Arch Otolaryngol Head Neck Surg 1989; 115:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/35\">",
"      Arjmand EM, Webber A. Audiometric findings in children with a large vestibular aqueduct. Arch Otolaryngol Head Neck Surg 2004; 130:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/36\">",
"      Rodriguez K, Shah RK, Kenna M. Anomalies of the middle and inner ear. Otolaryngol Clin North Am 2007; 40:81.",
"     </a>",
"    </li>",
"    <li>",
"     Queisser-Luft A, Stolz G, Wiesel A, et al. Associations between renal malformations and abnormally formed ears: Analysis of 32,589 newborns and newborn fetuses of the Mainz Congenital Birth Defect Monitoring System. In: XXI David W Smith Workshop on Malformation and Morphogenesis, San Diego 2000. p.60.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/38\">",
"      Kohelet D, Arbel E. A prospective search for urinary tract abnormalities in infants with isolated preauricular tags. Pediatrics 2000; 105:E61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/39\">",
"      Leung AK, Robson WL. Association of preauricular sinuses and renal anomalies. Urology 1992; 40:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12055/abstract/40\">",
"      Wang RY, Earl DL, Ruder RO, Graham JM Jr. Syndromic ear anomalies and renal ultrasounds. Pediatrics 2001; 108:E32.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6299 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-160F99BB66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_49_12055=[""].join("\n");
var outline_f11_49_12055=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EMBRYOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Outer ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Middle ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Inner ear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      OUTER EAR MALFORMATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Microtia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lop or outstanding ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Preauricular pits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Accessory auricular appendage/preauricular tag",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Aural atresia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MIDDLE EAR MALFORMATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      INNER EAR MALFORMATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ASSOCIATION WITH RENAL ANOMALIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6299\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6299|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/22/32111\" title=\"diagnostic image 1\">",
"      Large vestibular aqueduct",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6299|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/47/28404\" title=\"figure 1\">",
"      Pinna embryology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/6/28770\" title=\"figure 2\">",
"      Auditory canal embryology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/28/31173\" title=\"figure 3\">",
"      TM embryology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6299|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/41/28306\" title=\"picture 1\">",
"      Ossicle histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/10/36001\" title=\"picture 2\">",
"      Cochlear histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/32/19971\" title=\"picture 3\">",
"      Lop ear deformity 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/1/31775\" title=\"picture 4\">",
"      Preauricular pit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/30/30177\" title=\"picture 5\">",
"      Branchio oto renal syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/7/7282\" title=\"picture 6\">",
"      Preauricular cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/26/33199\" title=\"picture 7\">",
"      Preauricular pit excision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/33/37407\" title=\"picture 8\">",
"      Accessory auricle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/19/35135\" title=\"picture 9\">",
"      Aural atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/32/9728\" title=\"picture 10\">",
"      Mondini malformation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=related_link\">",
"      Acute otitis media in children: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42808?source=related_link\">",
"      Cholesteatoma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19574?source=related_link\">",
"      Principles of teratology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10935?source=related_link\">",
"      Renal hypoplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/15/250?source=related_link\">",
"      Syndromes with craniofacial abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29927?source=related_link\">",
"      Treatment of hearing impairment in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_49_12056="Clinical manifestations of osteoarthritis";
var content_f11_49_12056=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of osteoarthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/49/12056/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/49/12056/contributors\">",
"     Kenneth C Kalunian, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/49/12056/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/49/12056/contributors\">",
"     Peter Tugwell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/49/12056/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/49/12056/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/49/12056/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoarthritis (OA) was previously thought to be a normal consequence of aging, leading to the term &ldquo;degenerative joint disease.&rdquo; However, it is now realized that osteoarthritis results from the interplay of multiple factors, including joint integrity, genetics, local inflammation, mechanical forces, and cellular and biochemical processes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19114?source=see_link\">",
"     \"Pathogenesis of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An essential component to the assessment of OA is the correct attribution of signs and symptoms to the affected site. As an example, pain and other symptoms resulting from OA can be confused with soft tissue processes such as bursitis at periarticular sites; in addition, pain in a particular area may be referred from OA at other sites or may be due to a nonarticular process.",
"   </p>",
"   <p>",
"    The clinical manifestations of OA will be reviewed here. The diagnostic approach to and the management of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=see_link\">",
"     \"Diagnosis and classification of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=see_link\">",
"     \"Nonpharmacologic therapy of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=see_link\">",
"     \"Pharmacologic therapy of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12440?source=see_link\">",
"     \"Surgical therapy of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoarthritis most commonly presents in patients over 40 years of age. An overview of the clinical manifestations of this disorder is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef73969 \" href=\"UTD.htm?38/23/39292\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal symptom associated with OA is pain, which is typically exacerbated by activity and relieved by rest. With more advanced disease, pain may be noted with progressively less activity, eventually occurring at rest and at night. Episodic increases in pain and inflammation suggest synovitis caused by crystalline disease or trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Some patients ascribe fluctuating symptoms to changes in the weather, but the evidence for effects of varying barometric pressure, precipitation, and outdoor temperature is conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pain in OA is not caused directly by cartilage damage since cartilage is aneural. As a result, osteoarthritic radiologic changes are often incidentally noted in patients without symptoms at affected sites, when imaging studies are obtained for another reason.",
"   </p>",
"   <p>",
"    Stiffness is also a common complaint in patients with OA. Morning stiffness typically resolves less than thirty minutes after a patient awakens, but may recur following periods of inactivity, a phenomenon termed articular or inactivity gelling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several objective findings may be present upon physical examination of the patient with OA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tenderness to palpation of involved joints may be evident with or, more often, without associated signs of inflammation.",
"     </li>",
"     <li>",
"      Joint effusions may be present, which typically exhibit a mild pleocytosis, normal viscosity, and modestly elevated protein [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Crepitus is a common finding and is probably due to the disruption of the normally smooth articulating surfaces of the joints.",
"     </li>",
"     <li>",
"      Osteophytes may be palpable as bony enlargements along the periphery of the joint.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106450242\">",
"    <span class=\"h2\">",
"     Noninflammatory versus inflammatory OA",
"    </span>",
"    &nbsp;&mdash;&nbsp;We distinguish between patients with noninflammatory versus inflammatory OA. This distinction is particularly useful in treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=see_link\">",
"     \"Pharmacologic therapy of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both inflammatory and noninflammatory OA can be polyarticular, pauciarticular, or monoarticular. There are, however, differences in symptoms and physical findings [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with noninflammatory OA generally have pain and disability-related complaints as their only symptoms. Physical findings in affected joints include tenderness, bony prominence, and crepitus.",
"     </li>",
"     <li>",
"      Patients with inflammatory OA complain of articular swelling, morning stiffness lasting for more than 30 minutes, and night pain. Signs of inflammation include joint effusion on examination or radiography, warmth on palpation of the joint, and synovitis on arthroscopic examination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DISTRIBUTION AND CHARACTERISTICS OF SPECIFIC JOINT INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the characteristic clinical manifestations of OA are related to involvement of particular joints. The disorder does not affect all joints equally; it has a predilection for the fingers, knee, hip, and spine, and rarely affects the elbow, wrist, and ankle [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/8\">",
"     8",
"    </a>",
"    ]. If these atypical joints are involved in a patient suspected of having OA, the clinician should initiate a search for a history of trauma to or congenital abnormality of the joint, and for evidence of a systemic or crystalline disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hands",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hands are commonly involved in OA, occasionally resulting in debilitating pain and limited motion. Osteoarthritic enlargements of the distal and proximal interphalangeal joints are referred to as Heberden's and Bouchard's nodes, respectively (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81740 \" href=\"UTD.htm?30/58/31648\">",
"     image 1",
"    </a>",
"    ). The first carpometacarpal joint is also a common area affected in OA. Enlargement of this joint results in a squared appearance to the hand.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Feet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various portions of the foot may be involved in OA. The first metatarsophalangeal joint is often affected, possibly resulting in a hallux valgus or hallux rigidus. Involvement of the subtalar joint may be particularly troublesome during ambulation; pain is often elicited by inversion and eversion of the foot [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Knees",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteophytes, effusions, crepitus, and limitation of range of motion are all common signs of OA of the knee. However, findings on physical examination alone may underestimate the degree of knee involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/2\">",
"     2",
"    </a>",
"    ]. In advanced cases, malalignment may be apparent (genu varus or genu valgus), particularly when medial and lateral compartments are affected unequally. Cartilage loss due to osteoarthritis usually begins in the medial aspect of the tibiofemoral joint (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50213 \" href=\"UTD.htm?19/55/20350\">",
"     image 2",
"    </a>",
"    ) ; as a result, varus angulation (\"bow-legged\") occurs more commonly than valgus (\"knock-kneed\"). Femorotibial malalignment may be a risk factor for more rapid progression of OA of the knee [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/9\">",
"     9",
"    </a>",
"    ]. A fluctuant swelling along the posterior aspect of the knee, or Baker's cyst, is a common complication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation of the active adult patient with knee pain\", section on 'Popliteal cyst'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27016?source=see_link\">",
"     \"Popliteal (Baker's) cyst\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Involvement of the patellofemoral portions of the joint may be affected by malalignment. Among patients with established radiographic OA of the knee, genu varus and genu valgus are associated with more rapid progression of medial- and lateral patellofemoral OA, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hips",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain around the hip is common in patients with OA. It may be due to OA of the hip (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56376 \" href=\"UTD.htm?12/5/12383\">",
"     image 3",
"    </a>",
"    ) or to pain referred to the hip area from other structures, such as the lumbosacral spine [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/2\">",
"     2",
"    </a>",
"    ]. Similarly, OA of the hip may result in pain that is referred to distant structures (such as the knee) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another potential diagnostic problem is that patients frequently confuse the pain of greater trochanteric bursitis with OA of the hip. The pain from bursitis is felt laterally and does not limit motion; by comparison, OA of the hip is associated with pain and limited range of motion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14041?source=see_link\">",
"     \"Bursitis: An overview of clinical manifestations, diagnosis, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Spine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal involvement in OA is most common at spinal levels C5, T8, and L3, which represent the areas of greatest spinal flexibility [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/2\">",
"     2",
"    </a>",
"    ]. Two syndromes of clinical importance are due to OA of the lumbar apophyseal joints:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the cervical spine, osteophytes arising from the margins of the vertebral body (cervical spondylosis) may compromise the spinal canal. When sufficiently advanced, cervical spinal cord compression may result. Uncovertebral osteophytes can compromise the neural foramen (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef78738 \" href=\"UTD.htm?42/2/43055\">",
"       image 4",
"      </a>",
"      ) and impinge upon the exiting nerve root. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1418?source=see_link&amp;anchor=H8#H8\">",
"       \"Evaluation of the patient with neck pain and cervical spine disorders\", section on 'Cervical spondylosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lumbar apophyseal osteophytes (lumbar spondylosis) can cause spinal stenosis if they encroach into the intervertebral foramina",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the spinal canal. The resultant symptoms of low back pain with lower extremity radiation worsen with exertion, thereby mimicking vascular claudication, but may more rapidly resolve with rest. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1480?source=see_link\">",
"       \"Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Spondylolisthesis, a slipping of one vertebral body on another, typically affecting the apophyseal joints at L4 to L5, may occur with severe OA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diffuse idiopathic skeletal hyperostosis (DISH) is a syndrome of inappropriate bone formation at the insertions and along the course of ligaments and tendons. Although osteoarthritis is frequently present in patients with the DISH syndrome, the latter is thought to represent a distinct clinical entity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43960?source=see_link\">",
"     \"Diffuse idiopathic skeletal hyperostosis (DISH)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Shoulders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shoulder involvement in OA results in varied clinical manifestations, ranging from mild discomfort to destruction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms of a diseased glenohumeral joint (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59306 \" href=\"UTD.htm?23/46/24302\">",
"       image 5",
"      </a>",
"      ) typically include anterior shoulder pain that gradually worsens over years that is aggravated by movement. Glenohumeral OA is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26630?source=see_link\">",
"       \"Glenohumeral osteoarthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Involvement of the acromioclavicular joint may cause vague shoulder pain which may present a diagnostic dilemma [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Osteophytes located along the undersurface of the acromioclavicular joint (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68469 \" href=\"UTD.htm?32/21/33118\">",
"       image 6",
"      </a>",
"      ) may result in rotator cuff tendonitis or tears due to the juxtaposition of tendons with the inferior portion of the acromioclavicular joint. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=see_link\">",
"       \"Rotator cuff tendinopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The shoulder may rapidly deteriorate because of an aggressive form of OA which occurs in association with calcium crystalline disease (as observed in the Milwaukee shoulder syndrome) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=see_link\">",
"       \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs are helpful in assessing for the presence and severity of OA. Magnetic resonance imaging has been used primarily in a research setting but may have some clinical value in assessing for cartilage defects and bone marrow \"edema\".",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic changes in OA are insensitive, particularly with early disease, and correlate poorly with symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/12\">",
"     12",
"    </a>",
"    ]. When present, however, the specificity of the radiographic changes of OA often renders further diagnostic imaging unnecessary [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/13\">",
"     13",
"    </a>",
"    ]. The major radiographic features of OA include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Joint space narrowing",
"     </li>",
"     <li>",
"      Subchondral sclerosis",
"     </li>",
"     <li>",
"      Osteophytes",
"     </li>",
"     <li>",
"      Subchondral cysts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical relevance of each radiographic finding in OA appears to vary by joint. Minimal joint space of the hip is most closely correlated with pain [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/14\">",
"     14",
"    </a>",
"    ], while osteophytes arising from the patellofemoral and tibiofemoral joints of the knee correlate best with pain, and knee joint space narrowing best predicts disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     MR imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is not necessary for most patients with suggestive symptoms of OA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    typical plain radiographic features. However, MRI of the knee has a diagnostic role in patients with joint pain and symptoms such as locking, popping, or instability that suggest meniscal or ligamentous damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=see_link\">",
"     \"Evaluation of the active adult patient with knee pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of two MRI findings concomitantly correlates with painful OA of the knee: partial or full-thickness cartilage defects; and bone marrow \"edema\" as indicated by decreased T1 and increased T2 signal from the subchondral bone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In contrast, marrow edema alone does not appear to be closely associated with knee pain in patients with generalized osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/18,20\">",
"     18,20",
"    </a>",
"    ]. In addition, regions of medial or lateral tibial bone marrow edema that enlarge over time, or the presence of articular cartilage defects of the knee may be predictive of progression of cartilage space narrowing of the respective portion of the joint [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/19,21\">",
"     19,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increased prevalence of periarticular abnormalities in patients with OA of the knee has also been documented by MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/22\">",
"     22",
"    </a>",
"    ]. Approximately 15 percent of 376 patients with symptomatic OA of the knee had evidence of fluid collections indicative of tendonitis or bursitis while such collections were present in only 4 percent of those with radiographic evidence of OA without knee pain and in none of 24 controls with neither knee pain nor OA. It is uncertain whether treatment directed specifically at these areas of MRI abnormality would have a beneficial effect on knee pain. In a subset of patients who also had the painful knee examined, the areas of abnormality noted on MRI were not significantly correlated with areas of tenderness on exam.",
"   </p>",
"   <p>",
"    Although limited or no changes were seen on MRI in studies with small numbers of asymptomatic patients without radiographic OA, a larger study that analyzed patients over age 50 from the Framingham Osteoarthritis Study cohort found that MRI often reveals abnormal findings in such patients, regardless of whether pain is present [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/23\">",
"     23",
"    </a>",
"    ]. In the 710 patients evaluated without radiographic evidence of OA, the most common changes on MRI examination of the tibiofemoral joint were osteophytes, cartilage damage, and bone marrow abnormalities (in 74, 69, and 52 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/23\">",
"     23",
"    </a>",
"    ]. Moreover, at least one finding was present in similar numbers of patients, with or without pain (90 to 97 percent and 86 to 88 percent, depending upon the pain definition used). Changes were more common with advancing age.",
"   </p>",
"   <p>",
"    The rate of cartilage volume change may be estimated with MRI and appropriate image analysis software [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/24\">",
"     24",
"    </a>",
"    ]. MRI-based techniques for following the rate of progression of OA will remain research tools until they can be demonstrated to be cost-effective for clinical monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PATTERNS OF JOINT INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific set of joints involved in a given patient with OA tends to conform to one of several recognized clinical patterns. It is unknown whether these subsets, each with unique clinical features, reflect the alterations of a common disease process or are alternative syndromes with similarities of expression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The occurrence of monoarticular osteoarthritis in a young adult is often secondary to a congenital abnormality or previous trauma [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A pauciarticular form of OA is common in middle age and usually affects the large, weight-bearing joints of the lower extremities.",
"     </li>",
"     <li>",
"      Polyarticular or generalized OA is the most common form, typically affecting middle-aged or elderly women [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/13,25\">",
"       13,25",
"      </a>",
"      ]. The presence of Heberden's and Bouchard's nodes and involvement of the first carpometacarpal joint are common in these patients; the knees, hips, metatarsophalangeal joints and spine may also be involved [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The onset of the arthritis may be heralded by an initial, inflammatory phase. Erosive, inflammatory OA is a variant of this polyarticular form that follows a more aggressive course and frequently results in joint deformities. (See",
"      <a class=\"local\" href=\"#H106450242\">",
"       'Noninflammatory versus inflammatory OA'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DISEASE ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain systemic diseases have been associated with the development of \"secondary\" OA, including Wilson's disease and hemochromatosis. As an example, hemochromatosis may cause chondrocalcinosis and secondary OA in many joints, with a predilection for the second and third metacarpophalangeal joints. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29370?source=see_link\">",
"     \"Risk factors for and possible causes of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 1996 review summarized the available data regarding the natural history of OA [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/26\">",
"     26",
"    </a>",
"    ]. The disease is generally slowly progressive, although the disorder stabilizes in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/27\">",
"     27",
"    </a>",
"    ]. The course of those with progressive disease is usually one of intermittent worsening, rather than an inexorable linear decrease in function.",
"   </p>",
"   <p>",
"    The prognosis seems to differ according to the affected joint [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With hand OA, older age appears to be the strongest risk factor for progression.",
"     </li>",
"     <li>",
"      With hip OA, risk factors for progression to total hip replacement include female gender, night pain, and lower baseline functional capacity. In a community-based sample of 745 women more than 65 years of age, the presence of femoral, but not acetabular, osteophytes and of subchondral sclerosis were each associated with more rapid progression of joint space narrowing [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/28\">",
"       28",
"      </a>",
"      ]. Women with radiographic OA and hip pain at the initial screening were much more likely to proceed to joint replacement during the subsequent eight years than those who were asymptomatic (24 versus 3 percent). The value of an initial radiograph that demonstrates at least moderate OA in predicting further progression was independently confirmed in a community cohort of 1904 elderly men and women [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/29\">",
"       29",
"      </a>",
"      ]. The odds of having progressive worsening of hip joint space narrowing or total hip replacement in those with hip pain was increased 24-fold when compared with those with hip pain but minimal or no radiographic changes.",
"     </li>",
"     <li>",
"      With knee OA, a higher body mass index and polyarticular arthritis predict radiographic deterioration. Varus or valgus deformity of the knee correlates with later radiographic worsening of OA of the medial and lateral compartments, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/10,30\">",
"       10,30",
"      </a>",
"      ]. The greater the degree of deformity at the time of initial imaging, the greater the subsequent joint space narrowing and the more severe the functional consequences in the following 18 months. Synovial fluid levels of the carboxy-terminal propeptide of type II collagen (PIICP) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/31\">",
"       31",
"      </a>",
"      ] and urinary excretion of C-telopeptide fragments of type II collagen (CTX-II) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/32\">",
"       32",
"      </a>",
"      ] are correlated with the risk of radiographic progression; findings that currently have more relevance for research than clinical practice.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with OA also experience varying degrees of physical disability, and OA can adversely affect quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. OA is estimated to be the most common cause of disability in adults. A systematic review of incidence and prevalence of OA of the knee in persons older than 55 years in the United Kingdom reported an incidence of 25 percent per year, a prevalence of disability due to knee OA of 10 percent, and severe disability in about 2 to 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Worsening disability may be correlated with coping styles, in particular, avoidance of activity due to pain may lead to muscle weakness that may impact upon joint stability [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/36\">",
"     36",
"    </a>",
"    ]. Exercise may help to prevent such loss of strength and decrease disability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=see_link&amp;anchor=H9#H9\">",
"     \"Nonpharmacologic therapy of osteoarthritis\", section on 'Exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Joint laxity, impaired proprioception, greater body mass index, and more severe joint pain were each predictive of subsequent worsening in function in patients with OA of the knee; this was the conclusion of a systematic review [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/37\">",
"     37",
"    </a>",
"    ]. In contrast, patients with better muscle strength, better mental health, stronger social supports, and those who are better able to perform aerobic exercise experience less disability than those with lesser amounts of these factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85442765\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have suggested that OA is associated with excess mortality risk, although the precise cause could not be determined [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In a population-based study involving a cohort of 1163 patients with OA of the hip or knee, who were followed for a median of 14 years, the patients with OA had excess all cause mortality compared with the general population (standardized mortality ratio, SMR, 1.55, 95% CI 1.41-1.70) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12056/abstract/39\">",
"     39",
"    </a>",
"    ]. Among the potential causes, mortality was particularly increased for cardiovascular disease and dementia (SMR 1.71, 95% CI 1.49-1.98 and 1.99, 95% CI 1.22-3.25, respectively). Risk factors for death included a history of diabetes, cancer, or cardiovascular disease, and the presence of walking disability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/36/7747?source=see_link\">",
"       \"Patient information: Knee pain (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=see_link\">",
"       \"Patient information: Osteoarthritis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/4/24642?source=see_link\">",
"       \"Patient information: Knee pain (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/46/16098?source=see_link\">",
"       \"Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25658214\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteoarthritis (OA) most commonly presents in patients over 40 years of age. The principal symptom associated with OA is pain, which is typically exacerbated by activity and is relieved by rest. Other symptoms include stiffness, which typically resolves in the morning less than 30 minutes after awakening; the recurrence of stiffness that may occur with inactivity is termed gelling. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Findings on examination include tenderness to palpation, typically in the absence of inflammation; crepitus; bony enlargement; decreased range of motion; and malalignment. Synovial effusions, if present, show mild pleocytosis, normal viscosity, and modestly elevated protein. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A distinction can be made between noninflammatory and inflammatory OA. In addition to pain and disability-related complaints that may be seen in both types, patients with inflammatory OA may have articular swelling, morning stiffness lasting for more than 30 minutes, night pain, and signs of inflammation. (See",
"      <a class=\"local\" href=\"#H106450242\">",
"       'Noninflammatory versus inflammatory OA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      OA does not affect all joints equally; it has a predilection for the fingers, knees, hips, and spin, and rarely affects the elbows, wrists, and ankles. Many of the characteristic clinical manifestations of OA are related to involvement of particular joints. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Distribution and characteristics of specific joint involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plain radiographs are helpful in assessing for the presence and severity of OA. Magnetic resonance imaging (MRI) is generally not helpful in evaluating OA in routine clinical practice. The major radiographic features of OA include joint space narrowing, subchondral sclerosis, osteophytes, and subchondral cysts. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The specific set of joints involved in a given patient with OA tends to conform to one of several recognized clinical patterns. These include monoarticular OA in a young adult, often secondary to a congenital abnormality or to previous trauma; a pauciarticular form of OA, common in middle age and usually affecting the large, weightbearing joints of the lower extremities; and polyarticular or generalized OA, typically affecting middle-aged or older women, sometimes heralded by an initial inflammatory phase. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Patterns of joint involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      OA is generally slowly progressive, although it stabilizes in some patients. The course of those with progressive disease is usually one of intermittent worsening, rather than an inexorable linear decrease in function. The prognosis seems to differ according to the affected joint. Patients with OA may have excess all cause mortality compared with the general population. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/1\">",
"      Schumacher HR, Gordon G, Paul H, et al. Osteoarthritis, crystal deposition, and inflammation. Semin Arthritis Rheum 1971; 1:116.",
"     </a>",
"    </li>",
"    <li>",
"     Moskowitz RW, Holderbaum D. Clinical and laboratory findings in osteoarthritis. In: Arthritis and Allied Conditions, Koopman WJ (Ed), Williams &amp; Wilkins, Baltimore 2001. p.2216.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/3\">",
"      Quick DC. Joint pain and weather. A critical review of the literature. Minn Med 1997; 80:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/4\">",
"      McAlindon T, Formica M, Schmid CH, Fletcher J. Changes in barometric pressure and ambient temperature influence osteoarthritis pain. Am J Med 2007; 120:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/5\">",
"      Brennan SA, Harney T, Queally JM, et al. Influence of weather variables on pain severity in end-stage osteoarthritis. Int Orthop 2012; 36:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/6\">",
"      Fawthrop F, Hornby J, Swan A, et al. A comparison of normal and pathological synovial fluid. Br J Rheumatol 1985; 24:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/7\">",
"      Concoff AL, Singh R, Klarhman D, et al. A clinical algorithim for identifying occult crystalline disease in patients with osteoarthritis (abstract). Arthritis Rheum 1997; 40:S239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/8\">",
"      van Saase JL, van Romunde LK, Cats A, et al. Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. Ann Rheum Dis 1989; 48:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/9\">",
"      Brouwer GM, van Tol AW, Bergink AP, et al. Association between valgus and varus alignment and the development and progression of radiographic osteoarthritis of the knee. Arthritis Rheum 2007; 56:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/10\">",
"      Cahue S, Dunlop D, Hayes K, et al. Varus-valgus alignment in the progression of patellofemoral osteoarthritis. Arthritis Rheum 2004; 50:2184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/11\">",
"      Halverson PB, McCarty DJ, Cheung HS, Ryan LM. Milwaukee Shoulder syndrome: eleven additional cases with involvement of the knee in seven (basic calcium phosphate crystal deposition disease). Semin Arthritis Rheum 1984; 14:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/12\">",
"      Doherty M, Lanyon P. Epidemiology of peripheral joint osteoarthritis. Ann Rheum Dis 1996; 55:585.",
"     </a>",
"    </li>",
"    <li>",
"     Solomon L. Clinical features of osteoarthritis. In: Textbook of Rheumatology, Kelley WN, Hams ED Jr, Ruddy S, Sledge CB (Eds), WB Saunders, Philadelphia 1996. p.1383.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/14\">",
"      Croft P, Cooper C, Wickham C, Coggon D. Defining osteoarthritis of the hip for epidemiologic studies. Am J Epidemiol 1990; 132:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/15\">",
"      Kijowski R, Blankenbaker DG, Stanton PT, et al. Radiographic findings of osteoarthritis versus arthroscopic findings of articular cartilage degeneration in the tibiofemoral joint. Radiology 2006; 239:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/16\">",
"      McAlindon TE, Snow S, Cooper C, Dieppe PA. Radiographic patterns of osteoarthritis of the knee joint in the community: the importance of the patellofemoral joint. Ann Rheum Dis 1992; 51:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/17\">",
"      Altman RD, Fries JF, Bloch DA, et al. Radiographic assessment of progression in osteoarthritis. Arthritis Rheum 1987; 30:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/18\">",
"      Sowers MF, Hayes C, Jamadar D, et al. Magnetic resonance-detected subchondral bone marrow and cartilage defect characteristics associated with pain and X-ray-defined knee osteoarthritis. Osteoarthritis Cartilage 2003; 11:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/19\">",
"      Hunter DJ, Zhang Y, Niu J, et al. Increase in bone marrow lesions associated with cartilage loss: a longitudinal magnetic resonance imaging study of knee osteoarthritis. Arthritis Rheum 2006; 54:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/20\">",
"      Kornaat PR, Bloem JL, Ceulemans RY, et al. Osteoarthritis of the knee: association between clinical features and MR imaging findings. Radiology 2006; 239:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/21\">",
"      Ding C, Cicuttini F, Scott F, et al. Association of prevalent and incident knee cartilage defects with loss of tibial and patellar cartilage: a longitudinal study. Arthritis Rheum 2005; 52:3918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/22\">",
"      Hill CL, Gale DR, Chaisson CE, et al. Periarticular lesions detected on magnetic resonance imaging: prevalence in knees with and without symptoms. Arthritis Rheum 2003; 48:2836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/23\">",
"      Guermazi A, Niu J, Hayashi D, et al. Prevalence of abnormalities in knees detected by MRI in adults without knee osteoarthritis: population based observational study (Framingham Osteoarthritis Study). BMJ 2012; 345:e5339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/24\">",
"      Raynauld JP, Martel-Pelletier J, Berthiaume MJ, et al. Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes. Arthritis Rheum 2004; 50:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/25\">",
"      Cooper C, Egger P, Coggon D, et al. Generalized osteoarthritis in women: pattern of joint involvement and approaches to definition for epidemiological studies. J Rheumatol 1996; 23:1938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/26\">",
"      Hochberg MC. Prognosis of osteoarthritis. Ann Rheum Dis 1996; 55:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/27\">",
"      Kirwan JR, Elson CJ. Is the progression of osteoarthritis phasic? Evidence and implications. J Rheumatol 2000; 27:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/28\">",
"      Lane NE, Nevitt MC, Hochberg MC, et al. Progression of radiographic hip osteoarthritis over eight years in a community sample of elderly white women. Arthritis Rheum 2004; 50:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/29\">",
"      Reijman M, Hazes JM, Pols HA, et al. Role of radiography in predicting progression of osteoarthritis of the hip: prospective cohort study. BMJ 2005; 330:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/30\">",
"      Sharma L, Song J, Felson DT, et al. The role of knee alignment in disease progression and functional decline in knee osteoarthritis. JAMA 2001; 286:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/31\">",
"      Sugiyama S, Itokazu M, Suzuki Y, Shimizu K. Procollagen II C propeptide level in the synovial fluid as a predictor of radiographic progression in early knee osteoarthritis. Ann Rheum Dis 2003; 62:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/32\">",
"      Reijman M, Hazes JM, Bierma-Zeinstra SM, et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 2004; 50:2471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/33\">",
"      Dominick KL, Ahern FM, Gold CH, Heller DA. Health-related quality of life among older adults with arthritis. Health Qual Life Outcomes 2004; 2:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/34\">",
"      Losina E, Walensky RP, Reichmann WM, et al. Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. Ann Intern Med 2011; 154:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/35\">",
"      Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis 2001; 60:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/36\">",
"      Steultjens MP, Dekker J, Bijlsma JW. Avoidance of activity and disability in patients with osteoarthritis of the knee: the mediating role of muscle strength. Arthritis Rheum 2002; 46:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/37\">",
"      van Dijk GM, Dekker J, Veenhof C, et al. Course of functional status and pain in osteoarthritis of the hip or knee: a systematic review of the literature. Arthritis Rheum 2006; 55:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/38\">",
"      Hochberg MC. Mortality in osteoarthritis. Clin Exp Rheumatol 2008; 26:S120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12056/abstract/39\">",
"      N&uuml;esch E, Dieppe P, Reichenbach S, et al. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ 2011; 342:d1165.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5495 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-6CC31590FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_49_12056=[""].join("\n");
var outline_f11_49_12056=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25658214\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106450242\">",
"      Noninflammatory versus inflammatory OA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DISTRIBUTION AND CHARACTERISTICS OF SPECIFIC JOINT INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Feet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Knees",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hips",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Spine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Shoulders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MR imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PATTERNS OF JOINT INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DISEASE ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85442765\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25658214\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5495\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5495|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/58/31648\" title=\"diagnostic image 1\">",
"      Erosive hand osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/55/20350\" title=\"diagnostic image 2\">",
"      OA knee preop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/5/12383\" title=\"diagnostic image 3\">",
"      Hip osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/2/43055\" title=\"diagnostic image 4\">",
"      Foraminal encroachment xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/46/24302\" title=\"diagnostic image 5\">",
"      Glenohumeral osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/21/33118\" title=\"diagnostic image 6\">",
"      AC osteoarthritis plain xray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5495|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/23/39292\" title=\"table 1\">",
"      Manifestations of OA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14041?source=related_link\">",
"      Bursitis: An overview of clinical manifestations, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=related_link\">",
"      Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=related_link\">",
"      Diagnosis and classification of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43960?source=related_link\">",
"      Diffuse idiopathic skeletal hyperostosis (DISH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=related_link\">",
"      Evaluation of the active adult patient with knee pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1418?source=related_link\">",
"      Evaluation of the patient with neck pain and cervical spine disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26630?source=related_link\">",
"      Glenohumeral osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1480?source=related_link\">",
"      Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=related_link\">",
"      Nonpharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19114?source=related_link\">",
"      Pathogenesis of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/4/24642?source=related_link\">",
"      Patient information: Knee pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/36/7747?source=related_link\">",
"      Patient information: Knee pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=related_link\">",
"      Patient information: Osteoarthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/46/16098?source=related_link\">",
"      Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=related_link\">",
"      Pharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27016?source=related_link\">",
"      Popliteal (Baker's) cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29370?source=related_link\">",
"      Risk factors for and possible causes of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=related_link\">",
"      Rotator cuff tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12440?source=related_link\">",
"      Surgical therapy of osteoarthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_49_12057="Cookie theft picture for NIHSS and PedNIHSS";
var content_f11_49_12057=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F83406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F83406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 616px\">",
"   <div class=\"ttl\">",
"    Cookie theft picture for NIHSS and PedNIHSS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 596px; height: 450px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cookie theft picture to test story-telling for Item 9 Best language of NIHSS and&nbsp;PedNIHSS.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ichord RN, Bastian R, Abraham L, et al. Interrater reliability of the Pediatric National Institutes of Health Stroke Scale (PedNIHSS) in a multicenter study. Stroke 2011; 42:613. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_49_12057=[""].join("\n");
var outline_f11_49_12057=null;
var title_f11_49_12058="Hematopoietic cell transplantation in follicular lymphoma";
var content_f11_49_12058=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hematopoietic cell transplantation in follicular lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/49/12058/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/49/12058/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/49/12058/contributors\">",
"     Jonathan W Friedberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/49/12058/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/49/12058/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/49/12058/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/49/12058/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/49/12058/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follicular lymphoma (FL, previously called follicle center lymphoma) is the second most common type of non-Hodgkin lymphoma (NHL). It is the most common of the indolent NHLs defined as those lymphomas in which survival of the untreated patient is measured in years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial treatment of FL depends upon the stage of disease at presentation. Patients with early stage disease may be cured with radiation therapy, while patients with advanced stage disease are initially managed with an immunotherapy-based regimen (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    plus chemotherapy). The use of either autologous or allogeneic hematopoietic cell transplantation (HCT) in FL is controversial and the subject of ongoing clinical trials. Autologous HCT is not usually curative, but may result in prolonged remissions and has a low treatment-related mortality rate. In comparison, allogeneic HCT may cure a higher percentage of patients with advanced stage FL, but is associated with substantial treatment-related mortality.",
"   </p>",
"   <p>",
"    The use of HCT in FL is reviewed below. Other treatment options are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=see_link\">",
"     \"Treatment of relapsed or refractory follicular lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15464?source=see_link\">",
"     \"Primary cutaneous follicle center lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H693499\">",
"    <span class=\"h1\">",
"     DETERMINING TRANSPLANT ELIGIBILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The determination of transplant eligibility should be made based on a risk-benefit assessment, and the needs and wishes of the patient. Eligibility for HCT varies across countries and institutions and depends upon the type of transplantation (ie, allogeneic versus autologous) and the conditioning regimen (eg, myeloablative versus nonmyeloablative).",
"   </p>",
"   <p>",
"    In most centers in the United States, patients are considered eligible for nonmyeloablative allogeneic HCT if they are less than 70 years of age, with normal cardiac, liver, and renal function, and have a good performance status (ECOG performance status 0 or 1) (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"     table 1",
"    </a>",
"    ). For myeloablative allogeneic transplantation, eligibility is more restrictive in that patients should typically be less than 55 years of age.",
"   </p>",
"   <p>",
"    In general, age is not considered to be a strict inclusion or exclusion criterion for autologous HCT. In most centers in the United States, patients with one or more of the following factors are NOT considered eligible for autologous HCT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct bilirubin &gt;2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (34.2",
"      <span class=\"nowrap\">",
"       &micro;mol/liter)",
"      </span>",
"     </li>",
"     <li>",
"      Serum creatinine &gt;2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (221",
"      <span class=\"nowrap\">",
"       &micro;mol/liter)",
"      </span>",
"      unless on chronic stable dialysis",
"     </li>",
"     <li>",
"      Eastern Cooperative Oncology Group (ECOG) performance status 3 or 4 unless due to bone pain (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      New York Heart Association functional status Class III or IV (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179016822\">",
"    <span class=\"h1\">",
"     TIMING OF TRANSPLANT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal timing of hematopoietic cell transplantation (HCT) in follicular lymphoma is unknown. Outside of a clinical trial, HCT is reserved for patients with relapsed or refractory follicular lymphoma or for those with histologic transformation to a more aggressive histology. Among patients with relapsed follicular lymphoma, a choice between HCT and chemotherapy without HCT is made on an individual basis. HCT is generally preferred for patients with clinically aggressive disease as demonstrated by a short remission duration. This is primarily based upon prospective randomized trials that have demonstrated a survival benefit from HCT in patients with relapsed follicular lymphoma, but failed to demonstrate a survival benefit in patients with previously untreated disease. HCT is also a reasonable treatment option for select patients with follicular lymphoma that has transformed to a more aggressive non-Hodgkin lymphoma subtype. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=see_link\">",
"     \"Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H179016836\">",
"     'Relapsed disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Interpretation of the trials that have investigated the relative value of HCT versus combination chemotherapy alone for patients with follicular lymphoma is complicated by subsequent changes in the standard care of follicular lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Since these trials were performed, the routine incorporation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    or its radioimmunoconjugates into the standard treatment of follicular lymphoma has improved survival rates among patients who do not undergo HCT. Even when a survival advantage for HCT was noted, this may not have been evident had the combination chemotherapy treatment arms involved the addition of these agents. Conversely, when a survival advantage for HCT was not found, this may have been because the patients did not receive sufficient chemotherapy immediately before transplantation, leading to incomplete disease control",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infusion of occult lymphoma cells contaminating the stem cell infusate [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179016836\">",
"    <span class=\"h2\">",
"     Relapsed disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of patients treated for follicular lymphoma will have an initial response to therapy, but virtually all of these patients will ultimately develop progressive disease requiring subsequent treatment. While relapsed disease is typically sensitive to additional therapy, the duration of remission becomes shorter with each subsequent therapy. In addition, a subset of patients will transform to a more aggressive histology. The use of either autologous or allogeneic HCT in relapsed follicular lymphoma is controversial and the subject of numerous ongoing clinical trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=see_link\">",
"     \"Treatment of relapsed or refractory follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autologous HCT has a low treatment-related mortality rate and may prolong progression-free and overall survival rates in a subset of patients who are in complete remission or have minimal disease at the time of HCT. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Autologous HCT'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Myeloablative allogeneic HCT has a treatment-related mortality rate that approaches 40 percent, but may be curative in a highly selected cohort of patients. In contrast, reduced-intensity and nonmyeloablative allogeneic HCT appear to have a lower treatment-related mortality (approximately 10 to 20 percent) with long-term progression-free survival rates of approximately 60 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The decision to perform an HCT in an eligible patient with relapsed follicular lymphoma depends upon the aggressiveness of disease. Unfortunately, our ability to predict the aggressiveness of disease is limited. Follicular lymphoma is a heterogeneous entity and some patients may enjoy very long treatment-free intervals, while others develop progressive disease rapidly or chemotherapy refractory disease or histologic transformation early on in their course. Our best measures of disease aggressiveness are the length and quality of initial (and subsequent) remission(s) and the Follicular Lymphoma International Prognostic Index (FLIPI) (",
"    <a class=\"graphic graphic_table graphicRef55987 \" href=\"UTD.htm?36/23/37243\">",
"     table 3",
"    </a>",
"    ). However, even the FLIPI, while useful as a general prognostic guide, does not reliably distinguish those who will have an extremely rapid decline, since even in the high-risk group the 10-year survival rate is still 36 percent. Despite this uncertainty, patients with an initial remission duration significantly less than the median progression-free survival for an individual treatment regimen, and those with a high FLIPI score, are more likely to have a short remission duration and to transform to a more aggressive histology.",
"   </p>",
"   <p>",
"    Among patients with relapsed follicular lymphoma, we consider HCT for patients with clinically aggressive disease who have relapsed after initial treatment with a regimen that incorporates immunotherapy, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . In general, we consider HCT for patients with a remission duration significantly less than the median remission duration expected for a particular regimen. As an example, prospective trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    plus rituximab (R-CHOP) have reported median remission durations of approximately 6.8 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. As such, patients progressing within 18 to 24 months of initial treatment with R-CHOP might be considered for HCT. In comparison, the median remission duration for cyclophosphamide, vincristine, and prednisone plus rituximab (R-CVP) reported in prospective trials is 2.8 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. As such, a remission duration of 18 to 24 months after R-CVP is not unexpected; however, patients progressing within one year of R-CVP might be considered for HCT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=see_link&amp;anchor=H19675543#H19675543\">",
"     \"Initial treatment of advanced stage (III/IV) follicular lymphoma\", section on 'Chemoimmunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179016843\">",
"    <span class=\"h2\">",
"     Following histologic transformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with follicular lymphoma develop transformation to a more aggressive histology at a rate of approximately 3 percent per year. Histologic transformation from an indolent to an aggressive histology has been associated with a poor prognosis. The use of autologous HCT for patients with chemotherapy-sensitive transformed follicular lymphoma is supported by retrospective analyses and expert opinion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=see_link\">",
"     \"Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retrospective analyses have evaluated autologous HCT in patients with chemotherapy-sensitive disease and a good performance status after histologic transformation of follicular lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/12-19\">",
"     12-19",
"    </a>",
"    ]. With this approach, approximate four- to five-year disease-free and overall survival rates range from 30 to 50 and 40 to 65 percent, respectively:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A series of 19 patients who attained a minimal disease state and underwent anti B-cell purged autologous HCT within one year of histologic transformation reported a median survival of 4.4 years, with three patients (16 percent) in remission at over four years of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A series of 21 patients from Dana-Farber Cancer Institute treated with anti-B-cell purged autologous HCT for FL transformed into diffuse large B cell lymphoma reported no acute in-hospital deaths and an estimated five-year disease-free survival rate of 46 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/13\">",
"       13",
"      </a>",
"      ]. Patients who underwent histologic transformation within 18 months of diagnosis of follicular lymphoma had a significantly better overall survival when compared with patients who transformed later.",
"     </li>",
"     <li>",
"      A series of 50 patients from the European Bone Marrow Transplant Registry who underwent autologous HCT for transformed low grade non-Hodgkin lymphoma reported overall and progression-free survival rates at five years of 51 and 30 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/14\">",
"       14",
"      </a>",
"      ]. A subgroup of patients with residual chemotherapy-sensitive disease who attained a complete response after high-dose therapy had an overall survival rate at five years of 69 percent. All three patients with chemotherapy-resistant disease at the time of high-dose therapy died of relapsed or progressive disease.",
"     </li>",
"     <li>",
"      A series of 35 patients treated with high-dose therapy and unpurged autologous HCT reported an overall survival rate at five years of 37 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/15\">",
"       15",
"      </a>",
"      ]. Of the five patients &gt;60 years of age, all died as the result of treatment-related complications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Only small case series have been reported on the use of allogeneic HCT for patients with follicular lymphoma transformed to a more aggressive histology [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/20\">",
"     20",
"    </a>",
"    ]. For this population, allogeneic HCT should be reserved for use in the context of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12431938\">",
"    <span class=\"h2\">",
"     Previously untreated disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several prospective randomized trials examined the use of high dose chemotherapy followed by autologous HCT in the treatment of newly diagnosed follicular lymphoma. While some have demonstrated improvements in progression-free survival, none have shown an overall survival benefit. These trials are presented in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=see_link&amp;anchor=H19675571#H19675571\">",
"     \"Initial treatment of advanced stage (III/IV) follicular lymphoma\", section on 'Transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPE OF TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no clear consensus among experts regarding the ideal type of hematopoietic cell transplantation (HCT) for patients with follicular lymphoma. Options include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High dose chemotherapy with autologous HCT (hematologic rescue) (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Autologous HCT'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Nonmyeloablative or reduced intensity allogeneic HCT",
"     </li>",
"     <li>",
"      Myeloablative allogeneic HCT",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All three options appear to have a survival benefit for the treatment of relapsed follicular lymphoma, but differing risks:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a clear increase in toxicity (ie, short-term treatment related mortality plus the risk of secondary malignancy) when comparing conventional therapy with autologous HCT and allogeneic HCT, with an approximate risk of treatment related mortality of &lt;5 percent with conventional therapy (ie, no HCT), 10 to 20 percent with autologous HCT, and 20 to 25 percent with allogeneic HCT.",
"     </li>",
"     <li>",
"      Although there is shorter follow-up for series of patients who have undergone allogeneic HCT, there appears to be a parallel increase in efficacy, with a chance of possible long term disease-free remission ranging from zero percent with conventional therapy, 25 to 40 percent with autologous HCT, and 50 to 60 percent with allogeneic HCT.",
"     </li>",
"     <li>",
"      It is possible that the incremental benefit in each case outweighs the incremental toxicity. Indeed, the results of autologous HCT seem superior to those of salvage chemotherapy alone. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Autologous HCT'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A comparison of nonrandomized trials of these different procedures is limited by the use of different patient selection criteria for the different regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/11\">",
"     11",
"    </a>",
"    ]. Unfortunately, a randomized trial is difficult to perform in this circumstance. A multicenter trial comparing allogeneic to autologous transplantation was closed early due to poor accrual (NCT00096460).",
"   </p>",
"   <p>",
"    Small case series have suggested a benefit of allogeneic HCT over autologous HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. A larger registry-based analysis compared the use of HLA-identical sibling allogeneic HCT (176 patients), purged autologous HCT (131 patients), and unpurged autologous HCT (597 patients) in patients with follicular lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/23\">",
"     23",
"    </a>",
"    ]. The median follow-up of survivors was 36 months, 49 months, and 41 months for the three treatment groups, respectively. Although there was no statistically significant difference in rates of five-year survival (51, 62, and 55 percent, respectively), there was a trend towards decreased cumulative recurrence rates at five years with allogeneic HCT (21 versus 43 versus 58 percent, respectively). Given the shorter time to plateau of the allogeneic HCT survival curves, and the five-year median time to development of therapy-related myelodysplastic syndrome or acute myeloid leukemia after autologous HCT, a significant benefit of allogeneic HCT might emerge with longer follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Autologous HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous HCT may prolong progression-free and overall survival rates in a subset of patients who are in complete remission or have minimal disease at the time of HCT. Support for the use of autologous HCT comes from several retrospective analyses and a single randomized trial performed prior to the development of immunotherapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ) for follicular lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/3,18,24-27\">",
"     3,18,24-27",
"    </a>",
"    ]. Attempts to purge the autologous graft of remaining tumor cells using various techniques have yet to show a benefit. As such, we consider unpurged autologous HCT for patients with relapsed disease, especially in those with resistant disease and short remissions. Patients who relapse after autologous HCT may be considered for nonmyeloablative or reduced intensity allogeneic HCT.",
"   </p>",
"   <p>",
"    A European phase III randomized trial (the CUP trial) compared high-dose therapy followed by autologous HCT with combination chemotherapy in 89 patients with relapsed or progressive follicular lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/3\">",
"     3",
"    </a>",
"    ]. At a median follow-up of 69 months, patients treated with high-dose therapy followed by unpurged or purged autologous HCT had the following significant outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher progression-free survival rates at two years (55 to 58 versus 26 percent)",
"     </li>",
"     <li>",
"      Higher four-year overall survival rates (71 to 77 versus 46 percent)",
"     </li>",
"     <li>",
"      There was no clear evidence in support of purging",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above study was performed before",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    was available for the treatment of follicular lymphoma and has been criticized for the small numbers of patients in each arm of the trial. The tremendous responses seen with rituximab treatment have made some clinicians question whether the benefit of HCT still holds true in the rituximab era.",
"   </p>",
"   <p>",
"    A retrospective analysis of 254 patients with relapsed follicular lymphoma reported that patients treated with high dose therapy followed by autologous HCT had significantly higher rates of five-year event-free survival (51 versus 24 percent) and overall survival (70 versus 42 percent) when compared with patients who did not receive HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/24\">",
"     24",
"    </a>",
"    ]. When this analysis was limited to patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    as part of their salvage regimen, the benefit from HCT lost its statistical significance for both five-year event-free and overall survival. However, these results have not yet been confirmed in another patient cohort and it is unknown whether this effect would also be seen with the addition of rituximab to salvage therapy for patients initially treated with rituximab-containing therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99074682\">",
"    <span class=\"h3\">",
"     Long-term efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several mature single-institution and registry studies have reported on the long-term follow-up of autologous HCT for follicular lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/19,25,28-31\">",
"     19,25,28-31",
"    </a>",
"    ]. Across those studies, the 10-year progression-free survival is consistently in the 30 percent to 50 percent range. A tantalizing result of these studies is the appearance of a plateau in the survival curves between 10 and 15 years after autologous HCT, suggesting that this procedure may be curative for a quarter to a third of transplanted patients. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Investigators at Dana-Farber Cancer Institute and St. Bartholomew's Hospital performed a retrospective long-term analysis of 121 patients with follicular lymphoma undergoing autologous HCT in second or subsequent remission [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/25\">",
"       25",
"      </a>",
"      ]. As compared with a historical group of patients in second remission treated with conventional therapy, those undergoing autologous HCT had a significantly longer freedom from relapse (49 versus 11 percent at 15 years) and overall survival (53 versus 30 percent at 15 years).",
"      <br/>",
"      <br/>",
"      The incidence of fatal treatment-related myelodysplastic",
"      <span class=\"nowrap\">",
"       syndrome/acute",
"      </span>",
"      myeloid leukemia was 10 percent in those receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      plus total body irradiation followed by autologous HCT, many of whom were in complete remission from their lymphoma at the time of death. However, the finding of an apparent plateau in the remission duration curve at 48 percent at 12 years of follow-up suggests that prolonged freedom from recurrence may be achieved via this means [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/25\">",
"       25",
"      </a>",
"      ]. Whether similar long-term survival can be obtained using chemoimmunotherapy programs is not yet known.",
"     </li>",
"     <li>",
"      Long-term results are also available from Nebraska concerning a group of 248 patients with recurrent follicular lymphoma who were treated with autologous HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/30\">",
"       30",
"      </a>",
"      ]. After a median follow-up of six years for surviving patients, five-year overall and event-free survival rates were 63 and 44 percent, respectively. The timing of transplantation appeared to affect outcome, with the best results seen in patients in first or second relapse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even for patients who have relapsed after autologous HCT, nonmyeloablative (reduced intensity conditioning) allogeneic HCT affords the possibility of prolonged disease-free survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82834519\">",
"    <span class=\"h3\">",
"     Preparative regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the ideal preparative regimen prior to autologous HCT is not known, a regimen that incorporates immunotherapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ) or radioimmunotherapy appears safe and may clear the bone marrow and blood (and the resulting leukapheresis product) of malignant cells (ie, in vivo purging). These agents are incorporated into the treatment of most patients with relapsed or refractory follicular lymphoma whether or not subsequent autologous HCT is planned. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=see_link\">",
"     \"Treatment of relapsed or refractory follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early studies have reported superior outcomes among patients whose preparative regimen included one of these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/32-37\">",
"     32-37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty-five patients with indolent NHL, 14 of whom had relapsed or refractory follicular lymphoma, were treated with high-dose sequential chemotherapy with (chemoimmunotherapy, 15 patients) or without (chemotherapy, 10 patients) multiple courses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , followed by autologous HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/34\">",
"       34",
"      </a>",
"      ]. Complete clinical and molecular remissions were noted in all 14 patients treated with chemoimmunotherapy. Leukapheresis products were PCR-negative for malignant cells in 93 and 40 percent of those treated with chemoimmunotherapy or chemotherapy, respectively.",
"     </li>",
"     <li>",
"      In a pilot study, patients were treated with three courses of CHOP, followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      and HAM (high dose cytosine arabinoside and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      ), peripheral blood stem cell collection, high dose chemotherapy with TBI, and autologous transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/32\">",
"       32",
"      </a>",
"      ]. In the seven patients with follicular lymphoma and t(14;18), the leukapheresis product was negative by polymerase chain reaction (PCR) for t(14;18) after one or two courses of",
"      <span class=\"nowrap\">",
"       rituximab/HAM.",
"      </span>",
"      This contrasts with PCR positivity in 74 percent of 47 patients treated with the same regimen without rituximab [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A cohort study of 125 patients with follicular lymphoma undergoing autologous HCT compared those who received high dose radioimmunotherapy with those who received conventional high-dose therapy as preparative regimens prior to HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/35\">",
"       35",
"      </a>",
"      ]. Patients treated with radioimmunotherapy had significantly higher rates of progression-free survival (48 versus 29 percent) and overall survival (67 versus 53 percent) at five years. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of relapsed or refractory follicular lymphoma\", section on 'Radioimmunotherapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A choice among preparative regimens must take into account the center&rsquo;s experience, the short and long term toxicities of the regimen, and the patient&rsquo;s comorbidities. Historically, many of the trials that incorporated HCT into the treatment of follicular lymphoma used preparative regimens with total body irradiation. However, the possible association between total body irradiation and subsequent myelodysplastic syndrome has led many centers to switch to chemotherapy only preparative regimens (",
"    <a class=\"graphic graphic_table graphicRef50359 \" href=\"UTD.htm?25/26/26029\">",
"     table 4",
"    </a>",
"    ). The use of the HAM and high dose radioimmunotherapy regimens is primarily limited to the few centers that pioneered their development. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link&amp;anchor=H7#H7\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Chemotherapy without radiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82834335\">",
"    <span class=\"h3\">",
"     Stem cell collection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral blood progenitor cells (PBPCs) are preferred over bone marrow harvested grafts for autologous HCT by most groups due to quicker engraftment and a potential for less contamination of the infused cells with tumor cells. The various sources of hematopoietic stem cells are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=see_link&amp;anchor=H5#H5\">",
"     \"Hematopoietic support after hematopoietic cell transplantation\", section on 'Autologous PBPC transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The University of Nebraska has reported on the results of 100 patients treated with PBPCs. Four-year failure-free and overall survivals were 44 and 65 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/26\">",
"     26",
"    </a>",
"    ]. There was no statistically significant difference in the outcome between patients receiving unpurged marrow and those receiving PBPCs. Similar results using PBPCs have been reported by others [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although tumor cell contamination of PBPCs is generally less than that of unpurged bone marrow, tumor cells can still be seen in PBPC preparations. In other studies, patients whose PBPC had tumor cells detectable by polymerase chain reaction (PCR) tended to remain PCR positive in the bone marrow and peripheral blood after transplant and had a higher risk of relapse than those whose PBPCs were PCR negative [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/39-42\">",
"     39-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     In vitro tumor cell purging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high frequency of overt bone marrow and peripheral blood infiltration in follicular lymphoma has been seen as a major obstacle in pursuing autologous HCT, theoretically resulting in contamination of the reinfused marrow or peripheral blood stem cells with viable tumor cells. Accordingly, a number of maneuvers have been tried in order to circumvent this problem, including use of in vivo as well as in vitro tumor cell purging techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/3,29,43-45\">",
"     3,29,43-45",
"    </a>",
"    ]. In vitro attempts to purge the autologous graft of remaining tumor cells using various techniques have yet to show a benefit. As such, we do not manipulate the autologous graft prior to reinfusion outside of a clinical trial. In contrast, the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    or radioimmunotherapy prior to graft collection may result in less contamination of the graft product.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82834752\">",
"    <span class=\"h3\">",
"     Maintenance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance therapy refers to the prolonged administration of agents with low toxicity profiles in an attempt to prevent progression of disease. Maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    appears to improve progression-free survival rates, both after initial chemoimmunotherapy and after autologous HCT for relapsed or refractory disease. While we have incorporated the use of maintenance rituximab for most patients in both of these settings, toxicities are increased and the effect on overall survival is not clear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=see_link&amp;anchor=H19677456#H19677456\">",
"     \"Initial treatment of advanced stage (III/IV) follicular lymphoma\", section on 'Maintenance therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A multicenter phase III trial of patients with relapsed follicular lymphoma who achieved a complete response or very good partial remission to induction chemotherapy randomly assigned treatment in a 2x2 fashion to autologous HCT with or without in vivo",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    purging, each with or without two years of rituximab maintenance therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/46\">",
"     46",
"    </a>",
"    ]. An initial presentation, including a preliminary analysis of the first 280 patients, reported significantly superior rates of progression-free survival at five years among those who received in vivo purging (54 versus 48 percent) and among those who received rituximab maintenance (59 versus 43 percent). Progression-free survival at five years was the highest for patients who received both in vivo purging and rituximab maintenance (55 versus 38 percent, compared to those who received neither).",
"   </p>",
"   <p>",
"    For patients with relapsed or refractory follicular lymphoma who have had at least a partial response to chemoimmunotherapy prior to autologous HCT, we suggest maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    rather than observation. Even though maintenance therapy is designed to have a low toxicity profile, a decision regarding the use of maintenance therapy in an individual patient must take into consideration both the potential benefit from attaining a deeper response and the likelihood that this patient will tolerate the prolonged therapy. Maintenance rituximab is associated with a higher rate of late neutropenia, infections, the reactivation of viral infections (eg, hepatitis), and blunted responsiveness to vaccination (eg, influenza vaccination). The blunted response to vaccination may be of particular concern in patients who have undergone allogeneic transplantation because they require extensive re-immunization one to two years after the transplant. When administering maintenance rituximab, it is important to use one of the established regimens, such as that used in the study described above (rituximab 375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three months for a total of two years). There are no published data regarding the safety or efficacy of therapy extending beyond this; as such, rituximab maintenance should",
"    <strong>",
"     not",
"    </strong>",
"    exceed two years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Allogeneic HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic hematopoietic cell transplantation (HCT) takes advantage of the graft-versus-lymphoma effect to eradicate remaining disease and may cure at least half of patients with untransformed follicular lymphoma. There is agreement in case series that the outcomes of allogeneic HCT are better for patients with untransformed disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/47,48\">",
"     47,48",
"    </a>",
"    ] and for patients who have received fewer lines of prior therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myeloablative allogeneic HCT is associated with a treatment-related mortality rate of approximately 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/21,50,51\">",
"     21,50,51",
"    </a>",
"    ]. Given this high mortality rate, myeloablative allogeneic HCT is reserved for young, highly motivated patients with relapsed or resistant follicular lymphoma. In contrast, nonmyeloablative or reduced intensity conditioning regimens are associated with lower transplant related mortality. Nonmyeloablative conditioning regimens may be preferred for patients who have attained a second complete remission, but are not ideal candidates for conventional myeloablative HCT. In addition, patients who relapse after autologous HCT may be considered for nonmyeloablative (reduced intensity) allogeneic HCT.",
"   </p>",
"   <p>",
"    Allogeneic HCT is associated with mortality from short-term (eg, graft versus host disease, infection) and long-term (eg, myelodysplastic syndrome, acute myeloid leukemia, other secondary malignancies) transplant-related complications. The toxicity of this procedure is considerably greater than that of autologous HCT or conventional therapy. Even with nonmyeloablative or reduced intensity allogeneic HCT, the treatment-related mortality (TRM) at two to three years ranges from 15 to 25 percent and largely reflects deaths from graft-versus-host disease (GVHD) and infectious complications [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Moreover, the cumulative incidence of GVHD (especially chronic GVHD) is consistently above 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/47,48,52,53\">",
"     47,48,52,53",
"    </a>",
"    ]. Despite this toxicity, single-institution series and registry studies have reported progression-free survival rates at three to five years of 45 to 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/47-49,52-54\">",
"     47-49,52-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ideal preparative regimen for allogeneic HCT is unknown. The single-center and multicenter studies have reported similar survival rates for myeloablative and nonmyeloablative allogeneic HCT; moreover, a study from the Center for International Blood and Marrow Transplant Research (CIBMTR) showed no significant difference in progression-free or overall survival between the two modalities [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/53\">",
"     53",
"    </a>",
"    ]. In general, nonmyeloablative regimens are associated with lower TRM, but this benefit is offset by a higher risk of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/53,55-57\">",
"     53,55-57",
"    </a>",
"    ]. The choice between myeloablative and nonmyeloablative allogeneic HCT may be made based on the behavior of the disease, the quality of the remission, the age of the patient, and an assessment of the patient&rsquo;s comorbidities. (See",
"    <a class=\"local\" href=\"#H693499\">",
"     'Determining transplant eligibility'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Nonmyeloablative HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonmyeloablative and reduced intensity conditioning regimens have extended the eligibility of allogeneic HCT to older patients and those with comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/58-65\">",
"     58-65",
"    </a>",
"    ]. Even patients who have relapsed after autologous HCT, nonmyeloablative or reduced intensity conditioning allogeneic HCT affords the possibility of prolonged disease-free survival. The reported rates of progression-free survival after nonmyeloablative allogeneic HCT vary, but are reliably above 40 percent (and mostly around 60 percent) at two to three years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/47,59,66\">",
"     47,59,66",
"    </a>",
"    ]. In these series, there is also convincing evidence for a plateau in the progression-free survival curves suggesting that nonmyeloablative allogeneic HCT has curative potential. Specific regimens used for nonmyeloablative allogeneic HCT are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link&amp;anchor=H13#H13\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Nonmyeloablative and reduced intensity preparative regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is a survey of studies that have reported on the use of nonmyeloablative allogeneic HCT in patients with follicular lymphoma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The longest experience is from a prospective trial of nonmyeloablative HCT in 47 patients with chemotherapy sensitive relapsed follicular lymphoma given a preparative regimen of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for three days),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (750",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for three days), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      for one day plus 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      a day for three days) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/52\">",
"       52",
"      </a>",
"      ]. The two patients with a matched unrelated donor were also given equine antithymocyte globulin prior to the graft infusion. Graft-versus-host-disease (GVHD) prophylaxis consisted of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      . Acute GVHD was seen in 11 percent of patients. At a median follow-up of 107 months, the estimated rates of overall and progression-free survival at 11 years were 78 and 72 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another prospective trial, the same investigators treated 26 patients with relapsed or refractory (10 patients) follicular lymphoma with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and",
"      <sup>",
"       90",
"      </sup>",
"      Y-ibritumomab tiuxetan followed by allogeneic HCT from a 5 or 6 of 6 HLA-matched donor [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/67\">",
"       67",
"      </a>",
"      ]. At a median follow-up of 33 months, the estimated rates of progression-free and overall survival at three years were 85 and 88 percent, respectively. Similar outcomes were seen in patients with chemotherapy sensitive and chemotherapy refractory disease at the time of enrollment. The three-year cumulative incidence of chronic GVHD was 39 percent (24 percent extensive).",
"     </li>",
"     <li>",
"      A second study of nonmyeloablative allogeneic HCT involved 188 patients, including 52 previously-treated patients with indolent non-Hodgkin lymphoma (NHL), 85 percent of whom had chemosensitive disease; 29 percent had received a prior autologous HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/60\">",
"       60",
"      </a>",
"      ]. Nonmyeloablative allogeneic HCT yielded a 100-day treatment-related mortality of 11 percent and an estimated two-year overall survival rate of 65 percent. Predictors for an adverse outcome included chemotherapy-resistant disease and age &gt;50 years.",
"     </li>",
"     <li>",
"      A retrospective review of total body irradiation with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      followed by allogeneic HCT in 62 patients with chemotherapy-refractory indolent (75 percent) or transformed NHL reported three-year estimated overall and progression-free survival rates of 52 and 43 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/47\">",
"       47",
"      </a>",
"      ]. Patients with indolent disease and related donors had even higher overall and progression-free survival rates of 67 and 54 percent, respectively. Treatment was well tolerated. Long-term complications were limited. Survivors had a median Karnofsky performance status rating of 85 percent (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 5",
"      </a>",
"      ). Approximately half of patients suffered from extensive chronic GVHD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99075229\">",
"    <span class=\"h3\">",
"     Myeloablative HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;When compared with autologous HCT, myeloablative allogeneic HCT results in lower relapse rates but a higher treatment-related mortality of approximately 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/23,54,68\">",
"     23,54,68",
"    </a>",
"    ]. These differences were highlighted in a report from the International Bone Marrow Transplant Registry [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 176 patients with follicular lymphoma, 67 percent of whom had chemotherapy-sensitive disease at the time of HCT, Kaplan-Meier estimates of treatment-related mortality, recurrence rates, and overall survival at five years following allogeneic HCT were 30, 21, and 51 percent, respectively.",
"     </li>",
"     <li>",
"      During this same period of time, 597 patients with follicular lymphoma received unpurged autologous HCT; 82 percent were chemotherapy sensitive at the time of transplant. Kaplan-Meier estimates of treatment-related mortality, recurrence rates, and overall survival at five years following unpurged autologous HCT were 8, 58, and 55 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In an attempt to decrease transplant-related morbidity and mortality, T-cell depletion as a means of GVHD prophylaxis was performed on allografts in 16 patients with indolent lymphoma at the Medical College of Wisconsin [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/69\">",
"     69",
"    </a>",
"    ]. At five years, disease-free survival was 62 percent, with a relapse rate of 13 percent. A very low treatment related mortality following T-cell depletion has also been observed at the Dana-Farber Cancer Institute in patients with relapsed indolent lymphoma, with disease-free survival of 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/70\">",
"     70",
"    </a>",
"    ]. Longer follow-up is needed to determine whether or not T-cell depletion will interfere with a putative graft-versus-lymphoma effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179016252\">",
"    <span class=\"h1\">",
"     CARE DURING THE TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Care during the transplantation process depends largely upon the type of HCT performed:",
"   </p>",
"   <p>",
"    Autologous HCT has been performed in both the inpatient and outpatient settings. Approximately 24 hours after completion of the preparative chemotherapy, peripheral blood progenitor cells (PBPCs) are reinfused. A period of pancytopenia follows. Red blood cell and platelet transfusions are administered as necessary while hematopoietic colony-stimulating factors (ie, G-CSF) are used to speed neutrophil engraftment. Neutrophil engraftment usually occurs by day 12 and platelet counts are expected to recover to greater than 20,000 by day 16 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/49/12058/abstract/71\">",
"     71",
"    </a>",
"    ]. Red blood cell transfusion requirements during autologous HCT are usually minimal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=see_link\">",
"     \"Hematopoietic support after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Allogeneic HCT is largely reserved for the inpatient setting. Engraftment takes longer than for autologous HCT and infections are more common. Red blood cell and platelet transfusion requirements are usually moderate.",
"   </p>",
"   <p>",
"    Patients who undergo HCT are at risk for bacterial, viral, and fungal infections, the time course of which varies in the post-transplant period, according to the degree of immune deficiency and cytopenia induced by the transplantation procedure (",
"    <a class=\"graphic graphic_figure graphicRef64491 \" href=\"UTD.htm?4/7/4223\">",
"     figure 1",
"    </a>",
"    ). Prophylactic therapies to prevent infection, including antiviral and antifungal drugs, are recommended during a period of increased risk. In addition, all markers of potential infection must be investigated thoroughly. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=see_link\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/9/8339?source=see_link\">",
"       \"Patient information: Follicular lymphoma in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of either autologous or allogeneic hematopoietic cell transplantation (HCT) in follicular lymphoma is controversial and the subject of numerous ongoing clinical trials. Patients should be encouraged to participate in these trials, whenever possible.",
"     </li>",
"     <li>",
"      Among patients with newly diagnosed symptomatic follicular lymphoma, we recommend initial therapy with conventional dose chemotherapy plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      rather than high-dose chemotherapy followed by autologous HCT. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link\">",
"       \"Initial treatment of limited stage (I/II) follicular lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      HCT is reserved for patients with relapsed or refractory follicular lymphoma or for those with histologic transformation to a more aggressive histology. Transplantation, whether autologous or allogeneic, is mostly appropriate for patients with chemotherapy sensitive disease. While allogeneic HCT may rescue some patients with chemotherapy refractory disease, the outcomes are clearly inferior in this setting. (See",
"      <a class=\"local\" href=\"#H179016822\">",
"       'Timing of transplant'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To be eligible for HCT, the patient must have normal cardiac, liver, and renal function, and have a good performance status. In general, age is not considered to be a strict exclusion criterion for autologous HCT. In most centers in the United States, patients are considered eligible for nonmyeloablative allogeneic HCT if they are less than 70 years of age. For myeloablative allogeneic transplantation, patients should typically be less than 55 years of age. (See",
"      <a class=\"local\" href=\"#H693499\">",
"       'Determining transplant eligibility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision of whether or not to proceed with transplantation should be based on the patient&rsquo;s preference, condition, and the expected disease course. For the latter, there is no definitive score or metric. Among patients with relapsed follicular lymphoma, we consider HCT for patients with a remission duration significantly shorter than that expected for the initial chemotherapy regimen used. (See",
"      <a class=\"local\" href=\"#H179016836\">",
"       'Relapsed disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no clear consensus among experts regarding the ideal type of HCT for patients with follicular lymphoma. All three options appear to have a survival benefit for the treatment of relapsed follicular lymphoma, but differing risks:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      High dose chemotherapy with autologous HCT (hematologic rescue) has been associated with a low treatment-related mortality rate (10 to 20 percent), but higher relapse rate resulting in a potential cure rate of 25 to 40 percent. A preparative regimen that incorporates immunotherapy or radioimmunotherapy is generally preferred. As with other malignancies, peripheral blood progenitor cells are preferred over bone marrow harvested grafts. For eligible patients who relapse after a short initial response (ie, &lt;1 year) to chemoimmunotherapy and demonstrate chemotherapy sensitive disease, we suggest autologous HCT rather than treatment with chemoimmunotherapy alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In this same population, we suggest maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      following autologous HCT rather than observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This preference places a high value on a higher progression-free survival rate with unknown overall survival benefit following rituximab maintenance with the understanding that rituximab maintenance places the patient at risk for infections. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Autologous HCT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Allogeneic HCT is associated with a higher treatment related mortality rate (15 to 25 percent), but a higher potential rate of cure (50 to 60 percent). In some series, nonmyeloablative preparative regimens are associated with lower treatment related mortality, but this benefit is offset by a higher risk of relapse. Patients who relapse after autologous HCT should be strongly considered for nonmyeloablative allogeneic HCT.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/1\">",
"      Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004; 104:2667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/2\">",
"      Lenz G, Dreyling M, Schiegnitz E, et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004; 22:4926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/3\">",
"      Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21:3918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/4\">",
"      Sebban C, Mounier N, Brousse N, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006; 108:2540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/5\">",
"      Deconinck E, Foussard C, Milpied N, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 2005; 105:3817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/6\">",
"      van Besien K. Autologous transplantation for follicular lymphoma? Not too soon! Blood 2006; 108:2496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/7\">",
"      Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106:3725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/8\">",
"      Czuczman MS, Weaver R, Alkuzweny B, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22:4711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/9\">",
"      Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/10\">",
"      Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26:4579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/11\">",
"      Oliansky DM, Gordon LI, King J, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant 2010; 16:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/12\">",
"      Foran JM, Apostolidis J, Papamichael D, et al. High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. Ann Oncol 1998; 9:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/13\">",
"      Friedberg JW, Neuberg D, Gribben JG, et al. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant 1999; 5:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/14\">",
"      Williams CD, Harrison CN, Lister TA, et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 2001; 19:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/15\">",
"      Chen CI, Crump M, Tsang R, et al. Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. Br J Haematol 2001; 113:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/16\">",
"      Cao TM, Horning S, Negrin RS, et al. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. Biol Blood Marrow Transplant 2001; 7:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/17\">",
"      Berglund A, Enblad G, Carlson K, et al. Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma. Eur J Haematol 2000; 65:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/18\">",
"      Schouten HC, Bierman PJ, Vaughan WP, et al. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation. Blood 1989; 74:2579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/19\">",
"      Sabloff M, Atkins HL, Bence-Bruckler I, et al. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant 2007; 13:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/20\">",
"      Hamadani M, Awan FT, Elder P, et al. Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Leuk Lymphoma 2008; 49:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/21\">",
"      Ingram W, Devereux S, Das-Gupta EP, et al. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. Br J Haematol 2008; 141:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/22\">",
"      Hosing C, Saliba RM, McLaughlin P, et al. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol 2003; 14:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/23\">",
"      van Besien K, Loberiza FR Jr, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102:3521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/24\">",
"      Sebban C, Brice P, Delarue R, et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 2008; 26:3614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/25\">",
"      Rohatiner AZ, Nadler L, Davies AJ, et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 2007; 25:2554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/26\">",
"      Bierman PJ, Vose JM, Anderson JR, et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 1997; 15:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/27\">",
"      Brice P, Simon D, Bouabdallah R, et al. High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol 2000; 11:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/28\">",
"      Montoto S, Canals C, Rohatiner AZ, et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 2007; 21:2324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/29\">",
"      Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94:3325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/30\">",
"      Vose J, Bierman P, Lynch J, et al. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin's lymphoma: Effect of histologic grade (abstract). J Clin Oncol 2005; 23:576S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/31\">",
"      Vignot S, Mounier N, Larghero J, et al. High-dose therapy and autologous stem-cell transplantation can improve event-free survival for indolent lymphoma: a study using patients as their own controls. Cancer 2007; 109:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/32\">",
"      Voso MT, Pantel G, Weis M, et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 2000; 109:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/33\">",
"      Moos M, Schulz R, Martin S, et al. The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma. Leukemia 1998; 12:1971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/34\">",
"      Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/35\">",
"      Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 2003; 102:2351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/36\">",
"      Nademanee A, Forman S, Molina A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005; 106:2896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/37\">",
"      Krishnan A, Nademanee A, Fung HC, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/38\">",
"      Bastion Y, Brice P, Haioun C, et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995; 86:3257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/39\">",
"      Corradini P, Ladetto M, Zallio F, et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 2004; 22:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/40\">",
"      Haas R, Moos M, M&ouml;hle R, et al. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1996; 17:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/41\">",
"      Tarella C, Corradini P, Astolfi M, et al. Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions. Leukemia 1999; 13:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/42\">",
"      Ladetto M, Corradini P, Vallet S, et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 2002; 100:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/43\">",
"      Horning SJ, Negrin RS, Hoppe RT, et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 2001; 97:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/44\">",
"      Rohatiner AZ, Johnson PW, Price CG, et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994; 12:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/45\">",
"      Apostolidis J, Gupta RK, Grenzelias D, et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 2000; 18:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/46\">",
"      Pettengell R, Schmitz N, Gisselbrecht C, et al. Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy (abstract 8005). J Clin Oncol 2010; 28:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/47\">",
"      Rezvani AR, Storer B, Maris M, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/48\">",
"      Armand P, Kim HT, Ho VT, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008; 14:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/49\">",
"      Kuruvilla J, Pond G, Tsang R, et al. Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma. Biol Blood Marrow Transplant 2008; 14:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/50\">",
"      van Besien KW, Khouri IF, Giralt SA, et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol 1995; 13:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/51\">",
"      Kim SW, Tanimoto TE, Hirabayashi N, et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood 2006; 108:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/52\">",
"      Khouri IF, McLaughlin P, Saliba RM, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111:5530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/53\">",
"      Hari P, Carreras J, Zhang MJ, et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008; 14:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/54\">",
"      Toze CL, Barnett MJ, Connors JM, et al. Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. Br J Haematol 2004; 127:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/55\">",
"      Tomblyn M, Brunstein C, Burns LJ, et al. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008; 14:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/56\">",
"      Rodriguez R, Nademanee A, Ruel N, et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006; 12:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/57\">",
"      Sorror ML, Storer BE, Maloney DG, et al. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008; 111:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/58\">",
"      Khouri IF, Keating M, K&ouml;rbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/59\">",
"      Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98:3595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/60\">",
"      Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100:4310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/61\">",
"      Faulkner RD, Craddock C, Byrne JL, et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004; 103:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/62\">",
"      Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104:3865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/63\">",
"      de Lavallade H, Mohty M, El-Cheikh J, et al. Reduced-intensity conditioning allogeneic stem cell transplantation for patients with chemoresistant or relapsed follicular lymphoma. Br J Haematol 2006; 135:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/64\">",
"      Thomson KJ, Morris EC, Milligan D, et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 2010; 28:3695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/65\">",
"      Pi&ntilde;ana JL, Martino R, Gayoso J, et al. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica 2010; 95:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/66\">",
"      Abou-Nassar KE, Stevenson KE, Antin JH, et al. (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma. Bone Marrow Transplant 2011; 46:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/67\">",
"      Khouri IF, Saliba RM, Erwin WD, et al. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 2012; 119:6373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/68\">",
"      Avivi I, Montoto S, Canals C, et al. Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol 2009; 147:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/69\">",
"      Juckett M, Rowlings P, Hessner M, et al. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up. Bone Marrow Transplant 1998; 21:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/70\">",
"      Soiffer RJ, Freedman AS, Neuberg D, et al. CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 1998; 21:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/49/12058/abstract/71\">",
"      Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347:353.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4709 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-05EE575892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_49_12058=[""].join("\n");
var outline_f11_49_12058=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H693499\">",
"      DETERMINING TRANSPLANT ELIGIBILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179016822\">",
"      TIMING OF TRANSPLANT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179016836\">",
"      Relapsed disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179016843\">",
"      Following histologic transformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12431938\">",
"      Previously untreated disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPE OF TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Autologous HCT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H99074682\">",
"      - Long-term efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H82834519\">",
"      - Preparative regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H82834335\">",
"      - Stem cell collection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - In vitro tumor cell purging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H82834752\">",
"      - Maintenance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Allogeneic HCT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Nonmyeloablative HCT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H99075229\">",
"      - Myeloablative HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179016252\">",
"      CARE DURING THE TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4709\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4709|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/7/4223\" title=\"figure 1\">",
"      Infections after autologous HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4709|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 1\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/23/37243\" title=\"table 3\">",
"      Follic lymphoma int prog index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/26/26029\" title=\"table 4\">",
"      Chemotherapy preparative regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 5\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=related_link\">",
"      Hematopoietic support after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=related_link\">",
"      Initial treatment of advanced stage (III/IV) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=related_link\">",
"      Initial treatment of limited stage (I/II) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=related_link\">",
"      Overview of infections following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=related_link\">",
"      Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/9/8339?source=related_link\">",
"      Patient information: Follicular lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15464?source=related_link\">",
"      Primary cutaneous follicle center lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=related_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=related_link\">",
"      Treatment of relapsed or refractory follicular lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_49_12059="Hepatobiliary diseases in IBD";
var content_f11_49_12059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hepatobiliary diseases associated with inflammatory bowel disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diseases of the liver",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pericholangitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Steatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fibrosis and cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic hepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatic granulomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amyloidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatic abscess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug-induced hepatotoxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diseases of the biliary tract",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary sclerosing cholangitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholelithiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholangiocarcinoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_49_12059=[""].join("\n");
var outline_f11_49_12059=null;
var title_f11_49_12060="LTCF IC program guidelines";
var content_f11_49_12060=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    APIC guidelines for infection control programs in long-term care facilities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Develop protocols for detecting, treating, containing and",
"preventing transmission of potential nosocomial pathogens, including",
"specific guidelines for:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Handwashing and glove use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        A simple form of surveillance for nosocomial infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        An epidemic control program",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Resident and employee health program",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Employee infection control education program",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Housekeeping including food handling and laundry procedures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Guidelines for physical and occupational therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Engineering appropriate to specific diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Disposal of medical waste",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Establish written infection control policies and procedures, consistent with regulatory requirements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ensure that reliable microbiology laboratory support is available for relevant infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Establish communication with an Infectious Diseases physician and relevant health department officials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Include a mechanism for reporting of diseases of public health importance to appropriate authorities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        The program may also include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Environmental review",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Product evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Antibiotic monitoring",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    APIC: Association for Professionals in Infection Control and Epidemiology",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Smith PW, Rusnak PG. Am J Infect Control 1991; 19:198.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_49_12060=[""].join("\n");
var outline_f11_49_12060=null;
var title_f11_49_12061="Causes of bradycardia";
var content_f11_49_12061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of bradycardia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Intrinsic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Idiopathic degenerative disorder",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ischemic heart disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chronic ischemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acute myocardial infarction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypertensive heart disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cardiomyopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trauma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Surgery for congenital heart disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Heart transplant",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inflammation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Collagen vascular disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rheumatic fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pericarditis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Viral myocarditis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lyme disease (Borrelia burgdorfer I)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neuromuscular disorder",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Friedreich ataxia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            X-linked muscular dystrophy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Familial disorder",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Extrinsic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antiarrhythmic agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Class IA - quinidine, procainamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Class IC - propafenone, flecainide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Class II - &beta;-blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Class III - sotalol, amiodarone, dronedarone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Class IV - diltiazem, verapamil",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cardiac glycosides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Antihypertensive agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Clonidine, reserpine, methyldopa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Antipsychotic agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Lithium, phenothiazines, amitriptyline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Autonomically mediated",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Vasovagal syncope (cardioinhibitory)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Carotid sinus hypersensitivity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypothyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Intracranial hypertension",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypothermia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hyperkalemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypoxia",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fuster V, Walsh R, Harrington R. Hurst's the Heart, 13th ed, McGraw-Hill Professional, New York 2010. Copyright &copy; 2010 The McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_49_12061=[""].join("\n");
var outline_f11_49_12061=null;
var title_f11_49_12062="Time NSVT after MI outcome";
var content_f11_49_12062=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    NSVT soon after MI predicts lower late survival",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 482px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The prognostic importance of nonsustained ventricular tachycardia (NSVT) in patients with a myocardial infarction (MI) is related to the time of its occurrence after presentation. Panel A: NSVT is of prognostic significance for all time cutoffs &ge;13 hours. Panel B: Kaplan-Meier survival curves show that patients with NSVT occurring more than 24 hours after presentarion had poorer survival than those without NSVT or NSVT first occurring within 24 hours (p&lt;0.0001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Cheema, AN, Sheu, K, Parker, M, et al. Circulation 1998; 98:2030.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_49_12062=[""].join("\n");
var outline_f11_49_12062=null;
var title_f11_49_12063="Renin in HF";
var content_f11_49_12063=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F52302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F52302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Humoral adaptation to experimental heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 228px; height: 644px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sequential changes in mean aortic pressure, plasma renin activity, plasma aldosterone concentration, urinary sodium excretion, and plasma volume in a dog with moderate thoracic inferior vena cava constriction. There is initial hypotension, activation of the renin-angiotensin-aldosterone system, and a marked reduction in urinary Na+ excretion. By day 7, however, a new steady state is achieved in which renin and aldosterone levels and Na+ excretion have returned to baseline levels. The associated plasma volume expansion is responsible for restoring venous return to the heart, thereby allowing systemic hemodynamics to be normalized.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Watkins L Jr, Burton JA, Haber E, et al. J Clin Invest 1976; 57:1606. Copyright permission of the American Society for Clinical Investigation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_49_12063=[""].join("\n");
var outline_f11_49_12063=null;
